

WO0152862

Publication Title:

ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 BETA
EXPRESSION

Abstract:

Abstract of WO0152862

Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided. Data supplied from the esp@cenet database - Worldwide.

Courtesy of <http://v3.espacenet.com>

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
26 July 2001 (26.07.2001)

PCT

(10) International Publication Number
WO 01/52862 A1

(51) International Patent Classification⁷: **A61K 31/7088**,
31/7115, 31/712, 31/7125, C07H 21/00, C12N 5/06

(74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrell
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US01/01085

(22) International Filing Date: 12 January 2001 (12.01.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/489,765 19 January 2000 (19.01.2000) US

(71) Applicant (for all designated States except US): **ISIS
PHARMACEUTICALS, INC.** [US/US]; 2292 Faraday
Avenue, Carlsbad, CA 92008 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BUTLER, Made-
line, M.** [US/US]; 15951 Avenida Calma, Rancho Santa Fe,
CA 92091 (US). **MCKAY, Robert** [US/US]; 4780 Wilson
Avenue, #1, San Diego, CA 92116 (US). **MONIA, Brett,
P.** [US/US]; 7605 Nueva Castilla Way, La Costa, CA 92009
(US). **WYATT, Jacqueline, R.** [US/US]; 1065 Hymettus
Avenue, Encinitas, CA 92024 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 BETA EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of glycogen synthase kinase 3 beta. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding glycogen synthase kinase 3 beta. Methods of using these compounds for modulation of glycogen synthase kinase 3 beta expression and for treatment of diseases associated with expression of glycogen synthase kinase 3 beta are provided.



WO 01/52862 A1

5 **ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 BETA**
EXPRESSION

10 **FIELD OF THE INVENTION**

 The present invention provides compositions and methods for modulating the expression of glycogen synthase kinase 3 beta. In particular, this invention relates to antisense compounds, particularly oligonucleotides, specifically
15 hybridizable with nucleic acids encoding glycogen synthase kinase 3 beta. Such oligonucleotides have been shown to modulate the expression of glycogen synthase kinase 3 beta.

BACKGROUND OF THE INVENTION

20 One of the principal mechanisms by which cellular regulation is effected is through the transduction of extracellular signals across the membrane that in turn modulate biochemical pathways within the cell. Protein phosphorylation, orchestrated by enzymes known as kinases,
25 represents one course by which intracellular signals are propagated from molecule to molecule resulting in a cellular response. These signal transduction cascades are highly regulated and often overlapping as evidenced by the existence of many protein kinases as well as phosphatases, which remove
30 phosphate moieties. It is currently believed that a number of disease states and/or disorders are a result of either aberrant activation or functional mutations in the molecular components of kinase cascades. Consequently, considerable

attention has been devoted to the characterization of kinases, especially those involved in energy metabolism. One such kinase is glycogen synthase kinase 3.

Two different mammalian isoforms of glycogen synthase kinase 3 have been identified and each is encoded by a separate gene (Shaw et al., *Genome*, 1998, 41, 720-727; Woodgett, *Embo J.*, 1990, 9, 2431-2438). These isoforms, designated alpha and beta are expressed in different cell types and in different proportions. In some cells, the expression of these isoforms is under developmental control.

Glycogen synthase kinase 3 beta (also known as tau protein kinase I and GSK3B) is a serine/threonine protein kinase first described as a factor involved in glycogen synthesis. In this pathway, glycogen synthase kinase 3 phosphorylates select residues of glycogen synthase, the rate-limiting enzyme of glycogen deposition, thereby inactivating the enzyme. Therefore, glycogen synthase kinase 3 plays a predominant role in glycogen metabolism and has consequently been investigated as a potential therapeutic target in disease conditions such as diabetes and insulin regulation disorders (Cross et al., *FEBS Lett.*, 1997, 406, 211-215; Eldar-Finkelman et al., *Proc. Natl. Acad. Sci. U. S. A.*, 1996, 93, 10228-10233; Eldar-Finkelman and Krebs, *Proc. Natl. Acad. Sci. U. S. A.*, 1997, 94, 9660-9664; Eldar-Finkelman et al., *Diabetes*, 1999, 48, 1662-1666). Upstream, glycogen synthase kinase 3 beta is regulated by protein kinase C (Goode et al., *J. Biol. Chem.*, 1992, 267, 16878-16882).

It has been demonstrated that glycogen synthase kinase 3 beta is identical to a previously identified protein known as tau protein kinase-I, which phosphorylates tau, a protein component of paired helical filaments (PHF) found in Alzheimer's brains (Ishiguro et al., *FEBS Lett.*, 1993, 325,

167-172; Lovestone et al., *Neuroscience*, 1996, 73, 1145-1157; Yamaguchi et al., *Acta. Neuropathol. (Berl)*, 1996, 92, 232-241). The accumulation of these filaments is implicated in the pathological change in brain tissue (Ishiguro et al.,
5 *FEBS Lett.*, 1993, 325, 167-172). Glycogen synthase kinase 3 beta is enriched in brain and due to its ability to phosphorylate the tau protein, has been suggested to play a critical role in the development of Alzheimer's disease (Pei et al., *J. Neuropathol. Exp. Neurol.*, 1997, 56, 70-78).

10 Increased synthesis of the enzyme has been shown to increase the cellular maturation of another protein related to Alzheimer's disease, APP (Aplin et al., *Neuroreport.*, 1997, 8, 639-643). It is the aberrant processing of APP that leads to deposition of a beta amyloid in neuritic plaques.

15 Currently, there are no known therapeutic agents which effectively inhibit the synthesis of glycogen synthase kinase 3 beta and to date, investigative strategies aimed at modulating glycogen synthase kinase 3 beta function have involved the use of antibodies, antisense technology and
20 chemical inhibitors. A method for treating a biological condition mediated by glycogen synthase kinase 3 (GSK3) activity, said method comprising administering an effective amount of a pharmaceutical composition comprising a selective GSK3 inhibitor is disclosed in U.S. patent 6,057,117. The
25 selective GSK3 inhibitors generally disclosed include peptides, peptoids, small organic molecules, and polynucleotides. Disclosed in US Patent 5,837,853 are antisense oligonucleotides targeting the nucleotides which encode the first six amino acids of human glycogen synthase
30 kinase beta intended for use in the treatment of Alzheimer's disease and the prevention of neuronal cell death (Takashima et al., 1998). Disclosed in the PCT publication WO 97/41854 are methods to identify inhibitors of glycogen synthase

kinase 3 and the use of these inhibitors for the treatment of bipolar disorders, mania, Alzheimer's disease, diabetes and leukopenia (Klein and Melton, 1997). Other inhibitory compounds are disclosed in WO 99/21859. These heterocyclic compounds are intended for the treatment of a disease mediated by a protein kinase, one of which is glycogen synthase kinase 3 (Cheung et al., 1999). Two other compounds, lithium and valproate, both used in the treatment of bipolar disorders, have been shown to inhibit glycogen synthase kinase 3 beta activity (Chen et al., *J. Neurochem.*, 1999, 72, 1327-1330; Hong et al., *J. Biol. Chem.*, 1997, 272, 25326-25332).

There remains, however, a long felt need for additional agents capable of effectively inhibiting glycogen synthase kinase 3 beta function. The pharmacological modulation of glycogen synthase kinase 3 beta activity or expression may therefore be an appropriate point of therapeutic intervention in pathological conditions.

Antisense technology is emerging as an effective means for reducing the expression of specific gene products and may therefore prove to be uniquely useful in a number of therapeutic, diagnostic, and research applications for the modulation of glycogen synthase kinase 3 beta expression.

The present invention provides compositions and methods for modulating glycogen synthase kinase 3 beta expression.

SUMMARY OF THE INVENTION

The present invention is directed to antisense compounds, particularly oligonucleotides, which are targeted to a nucleic acid encoding glycogen synthase kinase 3 beta, and which modulate the expression of glycogen synthase kinase 3 beta. Pharmaceutical and other compositions comprising the antisense compounds of the invention are also provided.

Further provided are methods of modulating the expression of glycogen synthase kinase 3 beta in cells or tissues comprising contacting said cells or tissues with one or more of the antisense compounds or compositions of the invention.

5 Further provided are methods of treating an animal, particularly a human, suspected of having or being prone to a disease or condition associated with expression of glycogen synthase kinase 3 beta by administering a therapeutically or prophylactically effective amount of one or more of the

10 antisense compounds or compositions of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention employs oligomeric antisense compounds, particularly oligonucleotides, for use in

15 modulating the function of nucleic acid molecules encoding glycogen synthase kinase 3 beta, ultimately modulating the amount of glycogen synthase kinase 3 beta produced. This is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids

20 encoding glycogen synthase kinase 3 beta. As used herein, the terms "target nucleic acid" and "nucleic acid encoding glycogen synthase kinase 3 beta" encompass DNA encoding glycogen synthase kinase 3 beta, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from

25 such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid. This modulation of function of a target nucleic acid by compounds which specifically hybridize to it is generally referred to as

30 "antisense". The functions of DNA to be interfered with include replication and transcription. The functions of RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein

translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA. The overall effect of such interference with target nucleic acid function is modulation of the expression of glycogen synthase kinase 3 beta. In the context of the present invention, "modulation" means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene. In the context of the present invention, inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.

It is preferred to target specific nucleic acids for antisense. "Targeting" an antisense compound to a particular nucleic acid, in the context of this invention, is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated. This may be, for example, a cellular gene (or mRNA transcribed from the gene) whose expression is associated with a particular disorder or disease state, or a nucleic acid molecule from an infectious agent. In the present invention, the target is a nucleic acid molecule encoding glycogen synthase kinase 3 beta. The targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result. Within the context of the present invention, a preferred intragenic site is the region encompassing the translation initiation or termination codon of the open reading frame (ORF) of the gene. Since, as is known in the art, the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start

codon" or the "AUG start codon". A minority of genes have a translation initiation codon having the RNA sequence 5'-GUG, 5'-UUG or 5'-CUG, and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo. Thus, the terms "translation
5 initiation codon" and "start codon" can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or
10 more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions. In the context of the invention, "start codon" and "translation initiation codon" refer to the codon or
15 codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding glycogen synthase kinase 3 beta, regardless of the sequence(s) of such codons.

It is also known in the art that a translation
20 termination codon (or "stop codon") of a gene may have one of three sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively). The terms "start codon region" and "translation initiation codon region" refer to a portion of
25 such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon. Similarly, the terms "stop codon region" and "translation termination codon region" refer to a portion of such an mRNA or gene that
30 encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.

The open reading frame (ORF) or "coding region," which

is known in the art to refer to the region between the translation initiation codon and the translation termination codon, is also a region which may be targeted effectively. Other target regions include the 5' untranslated region
5 (5'UTR), known in the art to refer to the portion of an mRNA in the 5' direction from the translation initiation codon, and thus including nucleotides between the 5' cap site and the translation initiation codon of an mRNA or corresponding nucleotides on the gene, and the 3' untranslated region
10 (3'UTR), known in the art to refer to the portion of an mRNA in the 3' direction from the translation termination codon, and thus including nucleotides between the translation termination codon and 3' end of an mRNA or corresponding nucleotides on the gene. The 5' cap of an mRNA comprises an
15 N7-methylated guanosine residue joined to the 5'-most residue of the mRNA via a 5'-5' triphosphate linkage. The 5' cap region of an mRNA is considered to include the 5' cap structure itself as well as the first 50 nucleotides adjacent to the cap. The 5' cap region may also be a preferred target
20 region.

Although some eukaryotic mRNA transcripts are directly translated, many contain one or more regions, known as "introns," which are excised from a transcript before it is translated. The remaining (and therefore translated) regions
25 are known as "exons" and are spliced together to form a continuous mRNA sequence. mRNA splice sites, i.e., intron-exon junctions, may also be preferred target regions, and are particularly useful in situations where aberrant splicing is implicated in disease, or where an overproduction of a
30 particular mRNA splice product is implicated in disease. Aberrant fusion junctions due to rearrangements or deletions are also preferred targets. It has also been found that introns can also be effective, and therefore preferred,

target regions for antisense compounds targeted, for example, to DNA or pre-mRNA.

Once one or more target sites have been identified, oligonucleotides are chosen which are sufficiently
5 complementary to the target, i.e., hybridize sufficiently well and with sufficient specificity, to give the desired effect.

In the context of this invention, "hybridization" means hydrogen bonding, which may be Watson-Crick, Hoogsteen or
10 reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases. For example, adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds. "Complementary," as used herein, refers to the capacity for precise pairing between
15 two nucleotides. For example, if a nucleotide at a certain position of an oligonucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule, then the oligonucleotide and the DNA or RNA are considered to be complementary to each other at that
20 position. The oligonucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other. Thus, "specifically hybridizable" and "complementary" are terms
25 which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the oligonucleotide and the DNA or RNA target. It is understood in the art that the sequence of an antisense compound need not be 100%
30 complementary to that of its target nucleic acid to be specifically hybridizable. An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal

function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is
5 desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, and in the case of in vitro assays, under conditions in which the assays are performed.

Antisense compounds are commonly used as research
10 reagents and diagnostics. For example, antisense oligonucleotides, which are able to inhibit gene expression with exquisite specificity, are often used by those of ordinary skill to elucidate the function of particular genes. Antisense compounds are also used, for example, to
15 distinguish between functions of various members of a biological pathway. Antisense modulation has, therefore, been harnessed for research use.

The specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses.
20 Antisense oligonucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense oligonucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that
25 oligonucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans. In the context of this invention, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or
30 deoxyribonucleic acid (DNA) or mimetics thereof. This term includes oligonucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as oligonucleotides having non-naturally-

occurring portions which function similarly. Such modified or substituted oligonucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for
5 nucleic acid target and increased stability in the presence of nucleases.

While antisense oligonucleotides are a preferred form of antisense compound, the present invention comprehends other oligomeric antisense compounds, including but not limited to
10 oligonucleotide mimetics such as are described below. The antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides). Particularly preferred antisense compounds are antisense
15 oligonucleotides, even more preferably those comprising from about 12 to about 25 nucleobases. As is known in the art, a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and
20 the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the
25 sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are
30 generally preferred. Within the oligonucleotide structure, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5'

phosphodiester linkage.

Specific examples of preferred antisense compounds useful in this invention include oligonucleotides containing modified backbones or non-natural internucleoside linkages.

5 As defined in this specification, oligonucleotides having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone. For the purposes of this specification, and as sometimes referenced in the art,
10 modified oligonucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.

Preferred modified oligonucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates,
15 phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thiono-
20 alkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Various salts, mixed salts and free acid
25 forms are also included.

Representative United States patents that teach the preparation of the above phosphorus-containing linkages include, but are not limited to, U.S.: 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423;
30 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, certain of which are

commonly owned with this application, and each of which is herein incorporated by reference.

Preferred modified oligonucleotide backbones that do not include a phosphorus atom therein have backbones that are
5 formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from
10 the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino
15 backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH₂ component parts.

Representative United States patents that teach the preparation of the above oligonucleosides include, but are
20 not limited to, U.S.: 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070;
25 5,663,312; 5,633,360; 5,677,437; and 5,677,439, certain of which are commonly owned with this application, and each of which is herein incorporated by reference.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage, i.e., the backbone, of
30 the nucleotide units are replaced with novel groups. The base units are maintained for hybridization with an appropriate nucleic acid target compound. One such oligomeric compound, an oligonucleotide mimetic that has been

shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA compounds, the sugar-backbone of an oligonucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al., *Science*, 1991, 254, 1497-1500.

Most preferred embodiments of the invention are oligonucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH₂-NH-O-CH₂-, -CH₂-N(CH₃)-O-CH₂- [known as a methylene (methylimino) or MMI backbone], -CH₂-O-N(CH₃)-CH₂-, -CH₂-N(CH₃)-N(CH₃)-CH₂- and -O-N(CH₃)-CH₂-CH₂- [wherein the native phosphodiester backbone is represented as -O-P-O-CH₂-] of the above referenced U.S. patent 5,489,677, and the amide backbones of the above referenced U.S. patent 5,602,240. Also preferred are oligonucleotides having morpholino backbone structures of the above-referenced U.S. patent 5,034,506.

Modified oligonucleotides may also contain one or more substituted sugar moieties. Preferred oligonucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C₁ to C₁₀ alkyl or C₂ to C₁₀ alkenyl and alkynyl. Particularly preferred are O[(CH₂)_nO]_mCH₃, O(CH₂)_nOCH₃, O(CH₂)_nNH₂, O(CH₂)_nCH₃, O(CH₂)_nONH₂, and O(CH₂)_nON[(CH₂)_nCH₃]₂, where n and m are from 1 to about

10. Other preferred oligonucleotides comprise one of the following at the 2' position: C₁ to C₁₀ lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH₃, OCN, Cl, Br, CN, CF₃, OCF₃, SOCH₃, SO₂CH₃,
5 ONO₂, NO₂, N₃, NH₂, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic
10 properties of an oligonucleotide, and other substituents having similar properties. A preferred modification includes 2'-methoxyethoxy (2'-O-CH₂CH₂OCH₃, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504) i.e., an alkoxyalkoxy group. A further
15 preferred modification includes 2'-dimethylaminoethoxy, i.e., a O(CH₂)₂ON(CH₃)₂ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethylaminoethoxyethyl or 2'-DMAEOE), i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, also
20 described in examples hereinbelow.

Other preferred modifications include 2'-methoxy (2'-O-CH₃), 2'-aminopropoxy (2'-OCH₂CH₂CH₂NH₂) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the oligonucleotide, particularly the 3' position of the
25 sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligonucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the
30 preparation of such modified sugar structures include, but are not limited to, U.S.: 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909;

5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

5 Oligonucleotides may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and
10 uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine
15 and guanine, 2-thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo
20 particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further nucleobases include those disclosed in United States
25 Patent No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J.I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie*, International Edition, 1991, 30, 613, and those disclosed by
30 Sanghvi, Y.S., Chapter 15, *Antisense Research and Applications*, pages 289-302, Crooke, S.T. and Lebleu, B. , ed., CRC Press, 1993. Certain of these nucleobases are particularly useful for increasing the binding affinity of

the oligomeric compounds of the invention. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine
5 substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C (Sanghvi, Y.S., Crooke, S.T. and Lebleu, B., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278) and are presently preferred base substitutions, even more particularly when
10 combined with 2'-O-methoxyethyl sugar modifications.

Representative United States patents that teach the preparation of certain of the above noted modified nucleobases as well as other modified nucleobases include, but are not limited to, the above noted U.S. 3,687,808, as
15 well as U.S.: 4,845,205; 5,130,302; 5,134,066; 5,175,273; 5,367,066; 5,432,272; 5,457,187; 5,459,255; 5,484,908; 5,502,177; 5,525,711; 5,552,540; 5,587,469; 5,594,121, 5,596,091; 5,614,617; and 5,681,941, certain of which are commonly owned with the instant application, and each of
20 which is herein incorporated by reference, and United States patent 5,750,692, which is commonly owned with the instant application and also herein incorporated by reference.

Another modification of the oligonucleotides of the invention involves chemically linking to the oligonucleotide
25 one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. Such moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci. USA*, 1989, 86, 6553-6556), cholic
30 acid (Manoharan et al., *Bioorg. Med. Chem. Let.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., *Bioorg. Med. Chem. Let.*, 1993, 3, 2765-2770), a

thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; 5 Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethyl-ammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a 10 polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or 15 hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

Representative United States patents that teach the preparation of such oligonucleotide conjugates include, but are not limited to, U.S.: 4,828,979; 4,948,882; 5,218,105; 20 5,525,465; 5,541,313; 5,545,730; 5,552,538; 5,578,717, 5,580,731; 5,580,731; 5,591,584; 5,109,124; 5,118,802; 5,138,045; 5,414,077; 5,486,603; 5,512,439; 5,578,718; 5,608,046; 4,587,044; 4,605,735; 4,667,025; 4,762,779; 4,789,737; 4,824,941; 4,835,263; 4,876,335; 4,904,582; 25 4,958,013; 5,082,830; 5,112,963; 5,214,136; 5,082,830; 5,112,963; 5,214,136; 5,245,022; 5,254,469; 5,258,506; 5,262,536; 5,272,250; 5,292,873; 5,317,098; 5,371,241, 5,391,723; 5,416,203, 5,451,463; 5,510,475; 5,512,667; 5,514,785; 5,565,552; 5,567,810; 5,574,142; 5,585,481; 30 5,587,371; 5,595,726; 5,597,696; 5,599,923; 5,599,928 and 5,688,941, certain of which are commonly owned with the instant application, and each of which is herein incorporated

by reference.

It is not necessary for all positions in a given compound to be uniformly modified, and in fact more than one of the aforementioned modifications may be incorporated in a single compound or even at a single nucleoside within an oligonucleotide. The present invention also includes antisense compounds which are chimeric compounds. "Chimeric" antisense compounds or "chimeras," in the context of this invention, are antisense compounds, particularly oligonucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of an oligonucleotide compound. These oligonucleotides typically contain at least one region wherein the oligonucleotide is modified so as to confer upon the oligonucleotide increased resistance to nuclease degradation, increased cellular uptake, and/or increased binding affinity for the target nucleic acid. An additional region of the oligonucleotide may serve as a substrate for enzymes capable of cleaving RNA:DNA or RNA:RNA hybrids. By way of example, RNase H is a cellular endonuclease which cleaves the RNA strand of an RNA:DNA duplex. Activation of RNase H, therefore, results in cleavage of the RNA target, thereby greatly enhancing the efficiency of oligonucleotide inhibition of gene expression. Consequently, comparable results can often be obtained with shorter oligonucleotides when chimeric oligonucleotides are used, compared to phosphorothioate deoxyoligonucleotides hybridizing to the same target region. Cleavage of the RNA target can be routinely detected by gel electrophoresis and, if necessary, associated nucleic acid hybridization techniques known in the art.

Chimeric antisense compounds of the invention may be formed as composite structures of two or more

oligonucleotides, modified oligonucleotides, oligonucleosides and/or oligonucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S.: 5,013,830; 5,149,797; 5,220,007; 5,256,775; 5,366,878; 5,403,711; 5,491,133; 5,565,350; 5,623,065; 5,652,355; 5,652,356; and 5,700,922, certain of which are commonly owned with the instant application, and each of which is herein incorporated by reference in its entirety.

The antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis. Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, CA). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare oligonucleotides such as the phosphorothioates and alkylated derivatives.

The antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules. The compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption. Representative United States patents that teach the preparation of such uptake, distribution and/or absorption assisting formulations include, but are not limited to, U.S.: 5,108,921; 5,354,844; 5,416,016; 5,459,127; 5,521,291; 5,543,158; 5,547,932;

5,583,020; 5,591,721; 4,426,330; 4,534,899; 5,013,556;
5,108,921; 5,213,804; 5,227,170; 5,264,221; 5,356,633;
5,395,619; 5,416,016; 5,417,978; 5,462,854; 5,469,854;
5,512,295; 5,527,528; 5,534,259; 5,543,152; 5,556,948;
5 5,580,575; and 5,595,756, each of which is herein
incorporated by reference.

The antisense compounds of the invention encompass any
pharmaceutically acceptable salts, esters, or salts of such
esters, or any other compound which, upon administration to
10 an animal including a human, is capable of providing
(directly or indirectly) the biologically active metabolite
or residue thereof. Accordingly, for example, the disclosure
is also drawn to prodrugs and pharmaceutically acceptable
salts of the compounds of the invention, pharmaceutically
15 acceptable salts of such prodrugs, and other bioequivalents.

The term "prodrug" indicates a therapeutic agent that is
prepared in an inactive form that is converted to an active
form (i.e., drug) within the body or cells thereof by the
action of endogenous enzymes or other chemicals and/or
20 conditions. In particular, prodrug versions of the
oligonucleotides of the invention are prepared as SATE
[(S-acetyl-2-thioethyl) phosphate] derivatives according to
the methods disclosed in WO 93/24510 to Gosselin et al.,
published December 9, 1993 or in WO 94/26764 to Imbach et al.

25 The term "pharmaceutically acceptable salts" refers to
physiologically and pharmaceutically acceptable salts of the
compounds of the invention: i.e., salts that retain the
desired biological activity of the parent compound and do not
impart undesired toxicological effects thereto.

30 Pharmaceutically acceptable base addition salts are
formed with metals or amines, such as alkali and alkaline
earth metals or organic amines. Examples of metals used as
cations are sodium, potassium, magnesium, calcium, and the

like. Examples of suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-methylglucamine, and procaine (see, for example, Berge et al., "Pharmaceutical Salts," *J. of Pharma Sci.*, 1977, 66, 1-19). The base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner. The free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner. The free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention. As used herein, a "pharmaceutical addition salt" includes a pharmaceutically acceptable salt of an acid form of one of the components of the compositions of the invention. These include organic or inorganic acid salts of the amines. Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates. Other suitable pharmaceutically acceptable salts are well known to those skilled in the art and include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N-substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylemaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2-phenoxybenzoic acid,

2-acetoxybenzoic acid, embonic acid, nicotinic acid or
isonicotinic acid; and with amino acids, such as the 20
alpha-amino acids involved in the synthesis of proteins in
nature, for example glutamic acid or aspartic acid, and also
5 with phenylacetic acid, methanesulfonic acid, ethanesulfonic
acid, 2-hydroxyethanesulfonic acid, ethane-1,2-disulfonic
acid, benzenesulfonic acid, 4-methylbenzenesulfoic acid,
naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid,
2- or 3-phosphoglycerate, glucose-6-phosphate,
10 N-cyclohexylsulfamic acid (with the formation of cyclamates),
or with other acid organic compounds, such as ascorbic acid.
Pharmaceutically acceptable salts of compounds may also be
prepared with a pharmaceutically acceptable cation. Suitable
pharmaceutically acceptable cations are well known to those
15 skilled in the art and include alkaline, alkaline earth,
ammonium and quaternary ammonium cations. Carbonates or
hydrogen carbonates are also possible.

For oligonucleotides, preferred examples of
pharmaceutically acceptable salts include but are not limited
20 to (a) salts formed with cations such as sodium, potassium,
ammonium, magnesium, calcium, polyamines such as spermine and
spermidine, etc.; (b) acid addition salts formed with
inorganic acids, for example hydrochloric acid, hydrobromic
acid, sulfuric acid, phosphoric acid, nitric acid and the
25 like; (c) salts formed with organic acids such as, for
example, acetic acid, oxalic acid, tartaric acid, succinic
acid, maleic acid, fumaric acid, gluconic acid, citric acid,
malic acid, ascorbic acid, benzoic acid, tannic acid,
palmitic acid, alginic acid, polyglutamic acid,
30 naphthalenesulfonic acid, methanesulfonic acid,
p-toluenesulfonic acid, naphthalenedisulfonic acid,
polygalacturonic acid, and the like; and (d) salts formed
from elemental anions such as chlorine, bromine, and iodine.

The antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits. For therapeutics, an animal, preferably a human, suspected of having a disease or disorder
5 which can be treated by modulating the expression of glycogen synthase kinase 3 beta is treated by administering antisense compounds in accordance with this invention. The compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense
10 compound to a suitable pharmaceutically acceptable diluent or carrier. Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, inflammation or tumor formation, for example.

15 The antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding glycogen synthase kinase 3 beta, enabling sandwich and other assays to easily be constructed to exploit this fact. Hybridization of the antisense
20 oligonucleotides of the invention with a nucleic acid encoding glycogen synthase kinase 3 beta can be detected by means known in the art. Such means may include conjugation of an enzyme to the oligonucleotide, radiolabelling of the oligonucleotide or any other suitable detection means. Kits
25 using such detection means for detecting the level of glycogen synthase kinase 3 beta in a sample may also be prepared.

The present invention also includes pharmaceutical compositions and formulations which include the antisense
30 compounds of the invention. The pharmaceutical compositions of the present invention may be administered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Administration may

be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and
5 transdermal), oral or parenteral. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Oligonucleotides with at least one 2'-O-
10 methoxyethyl modification are believed to be particularly useful for oral administration.

Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids
15 and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable. Coated condoms, gloves and the like may also be useful.

Compositions and formulations for oral administration
20 include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.

Compositions and formulations for parenteral,
25 intrathecal or intraventricular administration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.

30 Pharmaceutical compositions of the present invention include, but are not limited to, solutions, emulsions, and liposome-containing formulations. These compositions may be generated from a variety of components that include, but are

not limited to, preformed liquids, self-emulsifying solids and self-emulsifying semisolids.

The pharmaceutical formulations of the present invention, which may conveniently be presented in unit dosage
5 form, may be prepared according to conventional techniques well known in the pharmaceutical industry. Such techniques include the step of bringing into association the active ingredients with the pharmaceutical carrier(s) or excipient(s). In general the formulations are prepared by
10 uniformly and intimately bringing into association the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product.

The compositions of the present invention may be
15 formulated into any of many possible dosage forms such as, but not limited to, tablets, capsules, liquid syrups, soft gels, suppositories, and enemas. The compositions of the present invention may also be formulated as suspensions in aqueous, non-aqueous or mixed media. Aqueous suspensions may
20 further contain substances which increase the viscosity of the suspension including, for example, sodium carboxymethylcellulose, sorbitol and/or dextran. The suspension may also contain stabilizers.

In one embodiment of the present invention the
25 pharmaceutical compositions may be formulated and used as foams. Pharmaceutical foams include formulations such as, but not limited to, emulsions, microemulsions, creams, jellies and liposomes. While basically similar in nature these formulations vary in the components and the consistency
30 of the final product. The preparation of such compositions and formulations is generally known to those skilled in the pharmaceutical and formulation arts and may be applied to the formulation of the compositions of the present invention.

Emulsions

The compositions of the present invention may be prepared and formulated as emulsions. Emulsions are typically heterogenous systems of one liquid dispersed in another in the form of droplets usually exceeding 0.1 μm in diameter. (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199; Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., Volume 1, p. 245; Block in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 2, p. 335; Higuchi et al., in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 301).

Emulsions are often biphasic systems comprising of two immiscible liquid phases intimately mixed and dispersed with each other. In general, emulsions may be either water-in-oil (w/o) or of the oil-in-water (o/w) variety. When an aqueous phase is finely divided into and dispersed as minute droplets into a bulk oily phase the resulting composition is called a water-in-oil (w/o) emulsion. Alternatively, when an oily phase is finely divided into and dispersed as minute droplets into a bulk aqueous phase the resulting composition is called an oil-in-water (o/w) emulsion. Emulsions may contain additional components in addition to the dispersed phases and the active drug which may be present as a solution in either the aqueous phase, oily phase or itself as a separate phase. Pharmaceutical excipients such as emulsifiers, stabilizers, dyes, and anti-oxidants may also be present in emulsions as needed. Pharmaceutical emulsions may also be multiple emulsions that are comprised of more than two phases such as, for example, in the case of oil-in-water-in-oil (o/w/o) and water-in-oil-in-water (w/o/w) emulsions. Such complex

formulations often provide certain advantages that simple binary emulsions do not. Multiple emulsions in which individual oil droplets of an o/w emulsion enclose small water droplets constitute a w/o/w emulsion. Likewise a
5 system of oil droplets enclosed in globules of water stabilized in an oily continuous provides an o/w/o emulsion.

Emulsions are characterized by little or no thermodynamic stability. Often, the dispersed or discontinuous phase of the emulsion is well dispersed into
10 the external or continuous phase and maintained in this form through the means of emulsifiers or the viscosity of the formulation. Either of the phases of the emulsion may be a semisolid or a solid, as is the case of emulsion-style ointment bases and creams. Other means of stabilizing
15 emulsions entail the use of emulsifiers that may be incorporated into either phase of the emulsion. Emulsifiers may broadly be classified into four categories: synthetic surfactants, naturally occurring emulsifiers, absorption bases, and finely dispersed solids (Idson, in *Pharmaceutical*
20 *Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199).

Synthetic surfactants, also known as surface active agents, have found wide applicability in the formulation of emulsions and have been reviewed in the literature (Rieger,
25 in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), Marcel Dekker, Inc., New York, N.Y., 1988, volume 1, p. 199). Surfactants are typically
30 amphiphilic and comprise a hydrophilic and a hydrophobic portion. The ratio of the hydrophilic to the hydrophobic nature of the surfactant has been termed the hydrophile/lipophile balance (HLB) and is a valuable tool in

categorizing and selecting surfactants in the preparation of formulations. Surfactants may be classified into different classes based on the nature of the hydrophilic group: nonionic, anionic, cationic and amphoteric (Rieger, in
5 *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 285).

Naturally occurring emulsifiers used in emulsion formulations include lanolin, beeswax, phosphatides, lecithin
10 and acacia. Absorption bases possess hydrophilic properties such that they can soak up water to form w/o emulsions yet retain their semisolid consistencies, such as anhydrous lanolin and hydrophilic petrolatum. Finely divided solids have also been used as good emulsifiers especially in
15 combination with surfactants and in viscous preparations. These include polar inorganic solids, such as heavy metal hydroxides, nonswelling clays such as bentonite, attapulgite, hectorite, kaolin, montmorillonite, colloidal aluminum silicate and colloidal magnesium aluminum silicate, pigments
20 and nonpolar solids such as carbon or glyceryl tristearate.

A large variety of non-emulsifying materials are also included in emulsion formulations and contribute to the properties of emulsions. These include fats, oils, waxes, fatty acids, fatty alcohols, fatty esters, humectants,
25 hydrophilic colloids, preservatives and antioxidants (Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335; Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New
30 York, N.Y., volume 1, p. 199).

Hydrophilic colloids or hydrocolloids include naturally occurring gums and synthetic polymers such as polysaccharides (for example, acacia, agar, alginic acid, carrageenan, guar

gum, karaya gum, and tragacanth), cellulose derivatives (for example, carboxymethylcellulose and carboxypropylcellulose), and synthetic polymers (for example, carbomers, cellulose ethers, and carboxyvinyl polymers). These disperse or swell
5 in water to form colloidal solutions that stabilize emulsions by forming strong interfacial films around the dispersed-phase droplets and by increasing the viscosity of the external phase.

Since emulsions often contain a number of ingredients
10 such as carbohydrates, proteins, sterols and phosphatides that may readily support the growth of microbes, these formulations often incorporate preservatives. Commonly used preservatives included in emulsion formulations include methyl paraben, propyl paraben, quaternary ammonium salts,
15 benzalkonium chloride, esters of p-hydroxybenzoic acid, and boric acid. Antioxidants are also commonly added to emulsion formulations to prevent deterioration of the formulation. Antioxidants used may be free radical scavengers such as tocopherols, alkyl gallates, butylated hydroxyanisole,
20 butylated hydroxytoluene, or reducing agents such as ascorbic acid and sodium metabisulfite, and antioxidant synergists such as citric acid, tartaric acid, and lecithin.

The application of emulsion formulations via dermatological, oral and parenteral routes and methods for
25 their manufacture have been reviewed in the literature (Idson, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Emulsion formulations for oral delivery have been very widely used because of reasons of ease of
30 formulation, efficacy from an absorption and bioavailability standpoint. (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Idson, in

Pharmaceutical Dosage Forms, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 199). Mineral-oil base laxatives, oil-soluble vitamins and high fat nutritive preparations are among the materials
5 that have commonly been administered orally as o/w emulsions.

In one embodiment of the present invention, the compositions of oligonucleotides and nucleic acids are formulated as microemulsions. A microemulsion may be defined as a system of water, oil and amphiphile which is a single
10 optically isotropic and thermodynamically stable liquid solution (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Typically microemulsions are systems that are prepared by first dispersing an oil in an
15 aqueous surfactant solution and then adding a sufficient amount of a fourth component, generally an intermediate chain-length alcohol to form a transparent system. Therefore, microemulsions have also been described as thermodynamically stable, isotropically clear dispersions of
20 two immiscible liquids that are stabilized by interfacial films of surface-active molecules (Leung and Shah, in: *Controlled Release of Drugs: Polymers and Aggregate Systems*, Rosoff, M., Ed., 1989, VCH Publishers, New York, pages 185-215). Microemulsions commonly are prepared via a combination
25 of three to five components that include oil, water, surfactant, cosurfactant and electrolyte. Whether the microemulsion is of the water-in-oil (w/o) or an oil-in-water (o/w) type is dependent on the properties of the oil and surfactant used and on the structure and geometric packing of
30 the polar heads and hydrocarbon tails of the surfactant molecules (Schott, in *Remington's Pharmaceutical Sciences*, Mack Publishing Co., Easton, PA, 1985, p. 271).

The phenomenological approach utilizing phase diagrams

has been extensively studied and has yielded a comprehensive knowledge, to one skilled in the art, of how to formulate microemulsions (Rosoff, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245; Block, in *Pharmaceutical Dosage Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 335). Compared to conventional emulsions, microemulsions offer the advantage of solubilizing water-insoluble drugs in a formulation of thermodynamically stable droplets that are formed spontaneously.

Surfactants used in the preparation of microemulsions include, but are not limited to, ionic surfactants, non-ionic surfactants, Brij 96, polyoxyethylene oleyl ethers, polyglycerol fatty acid esters, tetraglycerol monolaurate (ML310), tetraglycerol monooleate (MO310), hexaglycerol monooleate (PO310), hexaglycerol pentaoleate (PO500), decaglycerol monocaprate (MCA750), decaglycerol monooleate (MO750), decaglycerol sequioleate (SO750), decaglycerol decaoleate (DAO750), alone or in combination with cosurfactants. The cosurfactant, usually a short-chain alcohol such as ethanol, 1-propanol, and 1-butanol, serves to increase the interfacial fluidity by penetrating into the surfactant film and consequently creating a disordered film because of the void space generated among surfactant molecules. Microemulsions may, however, be prepared without the use of cosurfactants and alcohol-free self-emulsifying microemulsion systems are known in the art. The aqueous phase may typically be, but is not limited to, water, an aqueous solution of the drug, glycerol, PEG300, PEG400, polyglycerols, propylene glycols, and derivatives of ethylene glycol. The oil phase may include, but is not limited to, materials such as Captex 300, Captex 355, Capmul MCM, fatty

acid esters, medium chain (C8-C12) mono, di, and tri-glycerides, polyoxyethylated glyceryl fatty acid esters, fatty alcohols, polyglycolized glycerides, saturated polyglycolized C8-C10 glycerides, vegetable oils and silicone
5 oil.

Microemulsions are particularly of interest from the standpoint of drug solubilization and the enhanced absorption of drugs. Lipid based microemulsions (both o/w and w/o) have been proposed to enhance the oral bioavailability of drugs,
10 including peptides (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385-1390; Ritschel, *Meth. Find. Exp. Clin. Pharmacol.*, 1993, 13, 205). Microemulsions afford advantages of improved drug solubilization, protection of drug from enzymatic hydrolysis, possible enhancement of drug
15 absorption due to surfactant-induced alterations in membrane fluidity and permeability, ease of preparation, ease of oral administration over solid dosage forms, improved clinical potency, and decreased toxicity (Constantinides et al., *Pharmaceutical Research*, 1994, 11, 1385; Ho et al., *J. Pharm.*
20 *Sci.*, 1996, 85, 138-143). Often microemulsions may form spontaneously when their components are brought together at ambient temperature. This may be particularly advantageous when formulating thermolabile drugs, peptides or oligonucleotides. Microemulsions have also been effective in
25 the transdermal delivery of active components in both cosmetic and pharmaceutical applications. It is expected that the microemulsion compositions and formulations of the present invention will facilitate the increased systemic absorption of oligonucleotides and nucleic acids from the
30 gastrointestinal tract, as well as improve the local cellular uptake of oligonucleotides and nucleic acids within the gastrointestinal tract, vagina, buccal cavity and other areas of administration.

Microemulsions of the present invention may also contain additional components and additives such as sorbitan monostearate (Grill 3), Labrasol, and penetration enhancers to improve the properties of the formulation and to enhance
5 the absorption of the oligonucleotides and nucleic acids of the present invention. Penetration enhancers used in the microemulsions of the present invention may be classified as belonging to one of five broad categories - surfactants, fatty acids, bile salts, chelating agents, and non-chelating
10 non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p. 92). Each of these classes has been discussed above.

Liposomes

15 There are many organized surfactant structures besides microemulsions that have been studied and used for the formulation of drugs. These include monolayers, micelles, bilayers and vesicles. Vesicles, such as liposomes, have attracted great interest because of their specificity and the
20 duration of action they offer from the standpoint of drug delivery. As used in the present invention, the term "liposome" means a vesicle composed of amphiphilic lipids arranged in a spherical bilayer or bilayers.

Liposomes are unilamellar or multilamellar vesicles
25 which have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains the composition to be delivered. Cationic liposomes possess the advantage of being able to fuse to the cell wall. Non-cationic liposomes, although not able to fuse as efficiently
30 with the cell wall, are taken up by macrophages *in vivo*.

In order to cross intact mammalian skin, lipid vesicles must pass through a series of fine pores, each with a diameter less than 50 nm, under the influence of a suitable

transdermal gradient. Therefore, it is desirable to use a liposome which is highly deformable and able to pass through such fine pores.

Further advantages of liposomes include; liposomes
5 obtained from natural phospholipids are biocompatible and biodegradable; liposomes can incorporate a wide range of water and lipid soluble drugs; liposomes can protect encapsulated drugs in their internal compartments from metabolism and degradation (Rosoff, in *Pharmaceutical Dosage*
10 *Forms*, Lieberman, Rieger and Banker (Eds.), 1988, Marcel Dekker, Inc., New York, N.Y., volume 1, p. 245). Important considerations in the preparation of liposome formulations are the lipid surface charge, vesicle size and the aqueous volume of the liposomes.

15 Liposomes are useful for the transfer and delivery of active ingredients to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomes start to merge with the cellular membranes. As the
20 merging of the liposome and cell progresses, the liposomal contents are emptied into the cell where the active agent may act.

Liposomal formulations have been the focus of extensive investigation as the mode of delivery for many drugs. There
25 is growing evidence that for topical administration, liposomes present several advantages over other formulations. Such advantages include reduced side-effects related to high systemic absorption of the administered drug, increased accumulation of the administered drug at the desired target,
30 and the ability to administer a wide variety of drugs, both hydrophilic and hydrophobic, into the skin.

Several reports have detailed the ability of liposomes to deliver agents including high-molecular weight DNA into

the skin. Compounds including analgesics, antibodies, hormones and high-molecular weight DNAs have been administered to the skin. The majority of applications resulted in the targeting of the upper epidermis.

5 Liposomes fall into two broad classes. Cationic liposomes are positively charged liposomes which interact with the negatively charged DNA molecules to form a stable complex. The positively charged DNA/liposome complex binds to the negatively charged cell surface and is internalized in
10 an endosome. Due to the acidic pH within the endosome, the liposomes are ruptured, releasing their contents into the cell cytoplasm (Wang et al., *Biochem. Biophys. Res. Commun.*, 1987, 147, 980-985).

 Liposomes which are pH-sensitive or negatively-charged,
15 entrap DNA rather than complex with it. Since both the DNA and the lipid are similarly charged, repulsion rather than complex formation occurs. Nevertheless, some DNA is entrapped within the aqueous interior of these liposomes. pH-sensitive liposomes have been used to deliver DNA encoding the
20 thymidine kinase gene to cell monolayers in culture. Expression of the exogenous gene was detected in the target cells (Zhou et al., *Journal of Controlled Release*, 1992, 19, 269-274).

 One major type of liposomal composition includes
25 phospholipids other than naturally-derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Anionic liposome compositions generally are formed from dimyristoyl
30 phosphatidylglycerol, while anionic fusogenic liposomes are formed primarily from dioleoyl phosphatidylethanolamine (DOPE). Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC,

and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol.

Several studies have assessed the topical delivery of liposomal drug formulations to the skin. Application of
5 liposomes containing interferon to guinea pig skin resulted in a reduction of skin herpes sores while delivery of interferon via other means (e.g. as a solution or as an emulsion) were ineffective (Weiner et al., *Journal of Drug Targeting*, 1992, 2, 405-410). Further, an additional study
10 tested the efficacy of interferon administered as part of a liposomal formulation to the administration of interferon using an aqueous system, and concluded that the liposomal formulation was superior to aqueous administration (du Plessis et al., *Antiviral Research*, 1992, 18, 259-265).

15 Non-ionic liposomal systems have also been examined to determine their utility in the delivery of drugs to the skin, in particular systems comprising non-ionic surfactant and cholesterol. Non-ionic liposomal formulations comprising Novasome™ I (glyceryl dilaurate/cholesterol/polyoxyethylene-
20 10-stearyl ether) and Novasome™ II (glyceryl distearate/cholesterol/polyoxyethylene-10-stearyl ether) were used to deliver cyclosporin-A into the dermis of mouse skin. Results indicated that such non-ionic liposomal systems were effective in facilitating the deposition of cyclosporin-A
25 into different layers of the skin (Hu et al. *S.T.P. Pharma. Sci.*, 1994, 4, 6, 466).

Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes comprising one or more specialized lipids that, when
30 incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids. Examples of sterically stabilized liposomes are those in which part of the vesicle-forming lipid portion of

the liposome (A) comprises one or more glycolipids, such as monosialoganglioside G_{M1} , or (B) is derivatized with one or more hydrophilic polymers, such as a polyethylene glycol (PEG) moiety. While not wishing to be bound by any particular theory, it is thought in the art that, at least for sterically stabilized liposomes containing gangliosides, sphingomyelin, or PEG-derivatized lipids, the enhanced circulation half-life of these sterically stabilized liposomes derives from a reduced uptake into cells of the reticuloendothelial system (RES) (Allen et al., *FEBS Letters*, 1987, 223, 42; Wu et al., *Cancer Research*, 1993, 53, 3765).

Various liposomes comprising one or more glycolipids are known in the art. Papahadjopoulos et al. (*Ann. N.Y. Acad. Sci.*, 1987, 507, 64) reported the ability of monosialoganglioside G_{M1} , galactocerebroside sulfate and phosphatidylinositol to improve blood half-lives of liposomes. These findings were expounded upon by Gabizon et al. (*Proc. Natl. Acad. Sci. U.S.A.*, 1988, 85, 6949). U.S. Patent No. 4,837,028 and WO 88/04924, both to Allen et al., disclose liposomes comprising (1) sphingomyelin and (2) the ganglioside G_{M1} or a galactocerebroside sulfate ester. U.S. Patent No. 5,543,152 (Webb et al.) discloses liposomes comprising sphingomyelin. Liposomes comprising 1,2-sn-dimyristoylphosphatidylcholine are disclosed in WO 97/13499 (Lim et al.).

Many liposomes comprising lipids derivatized with one or more hydrophilic polymers, and methods of preparation thereof, are known in the art. Sunamoto et al. (*Bull. Chem. Soc. Jpn.*, 1980, 53, 2778) described liposomes comprising a nonionic detergent, $2C_{12}15G$, that contains a PEG moiety. Illum et al. (*FEBS Lett.*, 1984, 167, 79) noted that hydrophilic coating of polystyrene particles with polymeric glycols results in significantly enhanced blood half-lives.

Synthetic phospholipids modified by the attachment of carboxylic groups of polyalkylene glycols (e.g., PEG) are described by Sears (U.S. Patent Nos. 4,426,330 and 4,534,899). Klibanov et al. (*FEBS Lett.*, 1990, 268, 235) described experiments demonstrating that liposomes comprising phosphatidylethanolamine (PE) derivatized with PEG or PEG stearate have significant increases in blood circulation half-lives. Blume et al. (*Biochimica et Biophysica Acta*, 1990, 1029, 91) extended such observations to other PEG-derivatized phospholipids, e.g., DSPE-PEG, formed from the combination of distearoylphosphatidylethanolamine (DSPE) and PEG. Liposomes having covalently bound PEG moieties on their external surface are described in European Patent No. EP 0 445 131 B1 and WO 90/04384 to Fisher. Liposome compositions containing 1-20 mole percent of PE derivatized with PEG, and methods of use thereof, are described by Woodle et al. (U.S. Patent Nos. 5,013,556 and 5,356,633) and Martin et al. (U.S. Patent No. 5,213,804 and European Patent No. EP 0 496 813 B1). Liposomes comprising a number of other lipid-polymer conjugates are disclosed in WO 91/05545 and U.S. Patent No. 5,225,212 (both to Martin et al.) and in WO 94/20073 (Zalipsky et al.) Liposomes comprising PEG-modified ceramide lipids are described in WO 96/10391 (Choi et al.). U.S. Patent Nos. 5,540,935 (Miyazaki et al.) and 5,556,948 (Tagawa et al.) describe PEG-containing liposomes that can be further derivatized with functional moieties on their surfaces.

A limited number of liposomes comprising nucleic acids are known in the art. WO 96/40062 to Thierry et al. discloses methods for encapsulating high molecular weight nucleic acids in liposomes. U.S. Patent No. 5,264,221 to Tagawa et al. discloses protein-bonded liposomes and asserts that the contents of such liposomes may include an antisense RNA. U.S. Patent No. 5,665,710 to Rahman et al. describes

certain methods of encapsulating oligodeoxynucleotides in liposomes. WO 97/04787 to Love et al. discloses liposomes comprising antisense oligonucleotides targeted to the raf gene.

5 Transfersomes are yet another type of liposomes, and are highly deformable lipid aggregates which are attractive candidates for drug delivery vehicles. Transfersomes may be described as lipid droplets which are so highly deformable that they are easily able to penetrate through pores which
10 are smaller than the droplet. Transfersomes are adaptable to the environment in which they are used, e.g. they are self-optimizing (adaptive to the shape of pores in the skin), self-repairing, frequently reach their targets without fragmenting, and often self-loading. To make transfersomes
15 it is possible to add surface edge-activators, usually surfactants, to a standard liposomal composition. Transfersomes have been used to deliver serum albumin to the skin. The transfersome-mediated delivery of serum albumin has been shown to be as effective as subcutaneous injection
20 of a solution containing serum albumin.

Surfactants find wide application in formulations such as emulsions (including microemulsions) and liposomes. The most common way of classifying and ranking the properties of the many different types of surfactants, both natural and
25 synthetic, is by the use of the hydrophile/lipophile balance (HLB). The nature of the hydrophilic group (also known as the "head") provides the most useful means for categorizing the different surfactants used in formulations (Rieger, in *Pharmaceutical Dosage Forms*, Marcel Dekker, Inc., New York,
30 NY, 1988, p. 285).

If the surfactant molecule is not ionized, it is classified as a nonionic surfactant. Nonionic surfactants find wide application in pharmaceutical and cosmetic products

and are usable over a wide range of pH values. In general their HLB values range from 2 to about 18 depending on their structure. Nonionic surfactants include nonionic esters such as ethylene glycol esters, propylene glycol esters, glyceryl
5 esters, polyglyceryl esters, sorbitan esters, sucrose esters, and ethoxylated esters. Nonionic alkanolamides and ethers such as fatty alcohol ethoxylates, propoxylated alcohols, and ethoxylated/propoxylated block polymers are also included in this class. The polyoxyethylene surfactants are the most
10 popular members of the nonionic surfactant class.

If the surfactant molecule carries a negative charge when it is dissolved or dispersed in water, the surfactant is classified as anionic. Anionic surfactants include carboxylates such as soaps, acyl lactylates, acyl amides of
15 amino acids, esters of sulfuric acid such as alkyl sulfates and ethoxylated alkyl sulfates, sulfonates such as alkyl benzene sulfonates, acyl isethionates, acyl taurates and sulfosuccinates, and phosphates. The most important members of the anionic surfactant class are the alkyl sulfates and
20 the soaps.

If the surfactant molecule carries a positive charge when it is dissolved or dispersed in water, the surfactant is classified as cationic. Cationic surfactants include quaternary ammonium salts and ethoxylated amines. The
25 quaternary ammonium salts are the most used members of this class.

If the surfactant molecule has the ability to carry either a positive or negative charge, the surfactant is classified as amphoteric. Amphoteric surfactants include
30 acrylic acid derivatives, substituted alkylamides, N-alkylbetaines and phosphatides.

The use of surfactants in drug products, formulations and in emulsions has been reviewed (Rieger, in *Pharmaceutical*

Dosage Forms, Marcel Dekker, Inc., New York, NY, 1988, p. 285).

Penetration Enhancers

5 In one embodiment, the present invention employs various penetration enhancers to effect the efficient delivery of nucleic acids, particularly oligonucleotides, to the skin of animals. Most drugs are present in solution in both ionized and nonionized forms. However, usually only lipid soluble or
10 lipophilic drugs readily cross cell membranes. It has been discovered that even non-lipophilic drugs may cross cell membranes if the membrane to be crossed is treated with a penetration enhancer. In addition to aiding the diffusion of non-lipophilic drugs across cell membranes, penetration
15 enhancers also enhance the permeability of lipophilic drugs.

Penetration enhancers may be classified as belonging to one of five broad categories, i.e., surfactants, fatty acids, bile salts, chelating agents, and non-chelating non-surfactants (Lee et al., *Critical Reviews in Therapeutic Drug*
20 *Carrier Systems*, 1991, p.92). Each of the above mentioned classes of penetration enhancers are described below in greater detail.

Surfactants: In connection with the present invention,
25 surfactants (or "surface-active agents") are chemical entities which, when dissolved in an aqueous solution, reduce the surface tension of the solution or the interfacial tension between the aqueous solution and another liquid, with the result that absorption of oligonucleotides through the
30 mucosa is enhanced. In addition to bile salts and fatty acids, these penetration enhancers include, for example, sodium lauryl sulfate, polyoxyethylene-9-lauryl ether and polyoxyethylene-20-cetyl ether) (Lee et al., *Critical Reviews*

in *Therapeutic Drug Carrier Systems*, 1991, p.92); and perfluorochemical emulsions, such as FC-43. Takahashi et al., *J. Pharm. Pharmacol.*, 1988, 40, 252).

Fatty acids: Various fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid (n-decanoic acid), myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprinate, tricaprinate, monoolein (1-monooleoyl-*rac*-glycerol), dilaurin, caprylic acid, arachidonic acid, glycerol 1-monocaprinate, 1-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, C₁₀ alkyl esters thereof (e.g., methyl, isopropyl and *t*-butyl), and mono- and di-glycerides thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, p.92; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; El Hariri et al., *J. Pharm. Pharmacol.*, 1992, 44, 651-654).

Bile salts: The physiological role of bile includes the facilitation of dispersion and absorption of lipids and fat-soluble vitamins (Brunton, Chapter 38 in: Goodman & Gilman's *The Pharmacological Basis of Therapeutics*, 9th Ed., Hardman et al. Eds., McGraw-Hill, New York, 1996, pp. 934-935). Various natural bile salts, and their synthetic derivatives, act as penetration enhancers. Thus the term "bile salts" includes any of the naturally occurring components of bile as well as any of their synthetic derivatives. The bile salts of the invention include, for example, cholic acid (or its pharmaceutically acceptable sodium salt, sodium cholate), dehydrocholic acid (sodium dehydrocholate), deoxycholic acid (sodium deoxycholate), glucolic acid (sodium glucolate), glycholic acid (sodium glycocholate), glycodeoxycholic acid

(sodium glycodeoxycholate), taurocholic acid (sodium taurocholate), taurodeoxycholic acid (sodium taurodeoxycholate), chenodeoxycholic acid (sodium chenodeoxycholate), ursodeoxycholic acid (UDCA), sodium tauro-24,25-dihydro-fusidate (STDHF), sodium glycodihydrofusidate and polyoxyethylene-9-lauryl ether (POE) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Swinyard, Chapter 39 In: *Remington's Pharmaceutical Sciences*, 18th Ed., Gennaro, ed., Mack Publishing Co., Easton, PA, 1990, pages 782-783; Muranishi, *Critical Reviews in Therapeutic Drug Carrier Systems*, 1990, 7, 1-33; Yamamoto et al., *J. Pharm. Exp. Ther.*, 1992, 263, 25; Yamashita et al., *J. Pharm. Sci.*, 1990, 79, 579-583).

Chelating Agents: Chelating agents, as used in connection with the present invention, can be defined as compounds that remove metallic ions from solution by forming complexes therewith, with the result that absorption of oligonucleotides through the mucosa is enhanced. With regards to their use as penetration enhancers in the present invention, chelating agents have the added advantage of also serving as DNase inhibitors, as most characterized DNA nucleases require a divalent metal ion for catalysis and are thus inhibited by chelating agents (Jarrett, *J. Chromatogr.*, 1993, 618, 315-339). Chelating agents of the invention include but are not limited to disodium ethylenediaminetetraacetate (EDTA), citric acid, salicylates (e.g., sodium salicylate, 5-methoxysalicylate and homovanilate), N-acyl derivatives of collagen, laureth-9 and N-amino acyl derivatives of beta-diketones (enamines) (Lee et al., *Critical Reviews in Therapeutic Drug Carrier Systems*, 1991, page 92; Muranishi, *Critical Reviews in Therapeutic*

Drug Carrier Systems, 1990, 7, 1-33; Buur et al., *J. Control Rel.*, 1990, 14, 43-51).

Non-chelating non-surfactants: As used herein, non-
5 chelating non-surfactant penetration enhancing compounds can
be defined as compounds that demonstrate insignificant
activity as chelating agents or as surfactants but that
nonetheless enhance absorption of oligonucleotides through
the alimentary mucosa (Muranishi, *Critical Reviews in*
10 *Therapeutic Drug Carrier Systems*, 1990, 7, 1-33). This class
of penetration enhancers include, for example, unsaturated
cyclic ureas, 1-alkyl- and 1-alkenylazacyclo-alkanone
derivatives (Lee et al., *Critical Reviews in Therapeutic Drug*
Carrier Systems, 1991, page 92); and non-steroidal anti-
15 inflammatory agents such as diclofenac sodium, indomethacin
and phenylbutazone (Yamashita et al., *J. Pharm. Pharmacol.*,
1987, 39, 621-626).

Agents that enhance uptake of oligonucleotides at the
cellular level may also be added to the pharmaceutical and
20 other compositions of the present invention. For example,
cationic lipids, such as lipofectin (Junichi et al, U.S.
Patent No. 5,705,188), cationic glycerol derivatives, and
polycationic molecules, such as polylysine (Lollo et al., PCT
Application WO 97/30731), are also known to enhance the
25 cellular uptake of oligonucleotides.

Other agents may be utilized to enhance the penetration
of the administered nucleic acids, including glycols such as
ethylene glycol and propylene glycol, pyrrols such as 2-
pyrrol, azones, and terpenes such as limonene and menthone.

30

Carriers

Certain compositions of the present invention also
incorporate carrier compounds in the formulation. As used

herein, "carrier compound" or "carrier" can refer to a nucleic acid, or analog thereof, which is inert (*i.e.*, does not possess biological activity *per se*) but is recognized as a nucleic acid by *in vivo* processes that reduce the
5 bioavailability of a nucleic acid having biological activity by, for example, degrading the biologically active nucleic acid or promoting its removal from circulation. The coadministration of a nucleic acid and a carrier compound, typically with an excess of the latter substance, can result
10 in a substantial reduction of the amount of nucleic acid recovered in the liver, kidney or other extracirculatory reservoirs, presumably due to competition between the carrier compound and the nucleic acid for a common receptor. For example, the recovery of a partially phosphorothioate
15 oligonucleotide in hepatic tissue can be reduced when it is coadministered with polyinosinic acid, dextran sulfate, polycytidic acid or 4-acetamido-4'-isothiocyano-stilbene-2,2'-disulfonic acid (Miyao *et al.*, *Antisense Res. Dev.*, 1995, 5, 115-121; Takakura *et al.*, *Antisense & Nucl. Acid Drug Dev.*,
20 1996, 6, 177-183).

Excipients

In contrast to a carrier compound, a "pharmaceutical carrier" or "excipient" is a pharmaceutically acceptable
25 solvent, suspending agent or any other pharmacologically inert vehicle for delivering one or more nucleic acids to an animal. The excipient may be liquid or solid and is selected, with the planned manner of administration in mind, so as to provide for the desired bulk, consistency, etc.,
30 when combined with a nucleic acid and the other components of a given pharmaceutical composition. Typical pharmaceutical carriers include, but are not limited to, binding agents (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or

hydroxypropyl methylcellulose, etc.); fillers (e.g., lactose and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates or calcium hydrogen phosphate, etc.); lubricants (e.g.,
5 magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, etc.); disintegrants (e.g., starch, sodium starch glycolate, etc.); and wetting agents (e.g., sodium
10 lauryl sulphate, etc.).

Pharmaceutically acceptable organic or inorganic excipient suitable for non-parenteral administration which do not deleteriously react with nucleic acids can also be used to formulate the compositions of the present invention.

15 Suitable pharmaceutically acceptable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

20 Formulations for topical administration of nucleic acids may include sterile and non-sterile aqueous solutions, non-aqueous solutions in common solvents such as alcohols, or solutions of the nucleic acids in liquid or solid oil bases. The solutions may also contain buffers, diluents and other
25 suitable additives. Pharmaceutically acceptable organic or inorganic excipients suitable for non-parenteral administration which do not deleteriously react with nucleic acids can be used.

Suitable pharmaceutically acceptable excipients include,
30 but are not limited to, water, salt solutions, alcohol, polyethylene glycols, gelatin, lactose, amylose, magnesium stearate, talc, silicic acid, viscous paraffin, hydroxymethylcellulose, polyvinylpyrrolidone and the like.

Other Components

The compositions of the present invention may
5 additionally contain other adjunct components conventionally
found in pharmaceutical compositions, at their
art-established usage levels. Thus, for example, the
compositions may contain additional, compatible,
pharmaceutically-active materials such as, for example,
10 antipruritics, astringents, local anesthetics or
anti-inflammatory agents, or may contain additional materials
useful in physically formulating various dosage forms of the
compositions of the present invention, such as dyes,
flavoring agents, preservatives, antioxidants, opacifiers,
15 thickening agents and stabilizers. However, such materials,
when added, should not unduly interfere with the biological
activities of the components of the compositions of the
present invention. The formulations can be sterilized and,
if desired, mixed with auxiliary agents, e.g., lubricants,
20 preservatives, stabilizers, wetting agents, emulsifiers,
salts for influencing osmotic pressure, buffers, colorings,
flavorings and/or aromatic substances and the like which do
not deleteriously interact with the nucleic acid(s) of the
formulation.

25 Aqueous suspensions may contain substances which
increase the viscosity of the suspension including, for
example, sodium carboxymethylcellulose, sorbitol and/or
dextran. The suspension may also contain stabilizers.

Certain embodiments of the invention provide
30 pharmaceutical compositions containing (a) one or more
antisense compounds and (b) one or more other
chemotherapeutic agents which function by a non-antisense
mechanism. Examples of such chemotherapeutic agents include,

but are not limited to, anticancer drugs such as daunorubicin, dactinomycin, doxorubicin, bleomycin, mitomycin, nitrogen mustard, chlorambucil, melphalan, cyclophosphamide, 6-mercaptopurine, 6-thioguanine, cytarabine
5 (CA), 5-fluorouracil (5-FU), floxuridine (5-FUdR), methotrexate (MTX), colchicine, vincristine, vinblastine, etoposide, teniposide, cisplatin and diethylstilbestrol (DES). See, generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J.,
10 pages 1206-1228). Anti-inflammatory drugs, including but not limited to nonsteroidal anti-inflammatory drugs and corticosteroids, and antiviral drugs, including but not limited to ribivirin, vidarabine, acyclovir and ganciclovir, may also be combined in compositions of the invention. See,
15 generally, *The Merck Manual of Diagnosis and Therapy*, 15th Ed., Berkow et al., eds., 1987, Rahway, N.J., pages 2499-2506 and 46-49, respectively). Other non-antisense chemotherapeutic agents are also within the scope of this invention. Two or more combined compounds may be used
20 together or sequentially.

In another related embodiment, compositions of the invention may contain one or more antisense compounds, particularly oligonucleotides, targeted to a first nucleic acid and one or more additional antisense compounds targeted
25 to a second nucleic acid target. Numerous examples of antisense compounds are known in the art. Two or more combined compounds may be used together or sequentially.

The formulation of therapeutic compositions and their subsequent administration is believed to be within the skill
30 of those in the art. Dosing is dependent on severity and responsiveness of the disease state to be treated, with the course of treatment lasting from several days to several months, or until a cure is effected or a diminution of the

disease state is achieved. Optimal dosing schedules can be calculated from measurements of drug accumulation in the body of the patient. Persons of ordinary skill can easily determine optimum dosages, dosing methodologies and
5 repetition rates. Optimum dosages may vary depending on the relative potency of individual oligonucleotides, and can generally be estimated based on EC_{50} s found to be effective in in vitro and in vivo animal models. In general, dosage is from 0.01 ug to 100 g per kg of body weight, and may be given
10 once or more daily, weekly, monthly or yearly, or even once every 2 to 20 years. Persons of ordinary skill in the art can easily estimate repetition rates for dosing based on measured residence times and concentrations of the drug in bodily fluids or tissues. Following successful treatment, it
15 may be desirable to have the patient undergo maintenance therapy to prevent the recurrence of the disease state, wherein the oligonucleotide is administered in maintenance doses, ranging from 0.01 ug to 100 g per kg of body weight, once or more daily, to once every 20 years.

20 While the present invention has been described with specificity in accordance with certain of its preferred embodiments, the following examples serve only to illustrate the invention and are not intended to limit the same.

25 EXAMPLES

Example 1

Nucleoside Phosphoramidites for Oligonucleotide Synthesis Deoxy and 2'-alkoxy amidites

2'-Deoxy and 2'-methoxy beta-cyanoethyl diisopropyl
30 phosphoramidites were purchased from commercial sources (e.g. Chemgenes, Needham MA or Glen Research, Inc. Sterling VA). Other 2'-O-alkoxy substituted nucleoside amidites are prepared as described in U.S. Patent 5,506,351, herein

incorporated by reference. For oligonucleotides synthesized using 2'-alkoxy amidites, the standard cycle for unmodified oligonucleotides was utilized, except the wait step after pulse delivery of tetrazole and base was increased to 360
5 seconds.

Oligonucleotides containing 5-methyl-2'-deoxycytidine (5-Me-C) nucleotides were synthesized according to published methods [Sanghvi, et. al., *Nucleic Acids Research*, 1993, 21, 3197-3203] using commercially available phosphoramidites
10 (Glen Research, Sterling VA or ChemGenes, Needham MA).

2'-Fluoro amidites

2'-Fluorodeoxyadenosine amidites

2'-fluoro oligonucleotides were synthesized as described
15 previously [Kawasaki, et. al., *J. Med. Chem.*, 1993, 36, 831-841] and United States patent 5,670,633, herein incorporated by reference. Briefly, the protected nucleoside N6-benzoyl-2'-deoxy-2'-fluoroadenosine was synthesized utilizing commercially available 9-beta-D-arabinofuranosyladenine as
20 starting material and by modifying literature procedures whereby the 2'-alpha-fluoro atom is introduced by a S_N2-displacement of a 2'-beta-trityl group. Thus N6-benzoyl-9-beta-D-arabinofuranosyladenine was selectively protected in moderate yield as the 3',5'-ditetrahydropyranyl (THP)
25 intermediate. Deprotection of the THP and N6-benzoyl groups was accomplished using standard methodologies and standard methods were used to obtain the 5'-dimethoxytrityl-(DMT) and 5'-DMT-3'-phosphoramidite intermediates.

30 2'-Fluorodeoxyguanosine

The synthesis of 2'-deoxy-2'-fluoroguanosine was accomplished using tetraisopropylidisiloxanyl (TPDS) protected 9-beta-D-arabinofuranosylguanine as starting material, and

conversion to the intermediate diisobutyryl-arabinofuranosylguanosine. Deprotection of the TPDS group was followed by protection of the hydroxyl group with THP to give diisobutyryl di-THP protected arabinofuranosylguanine.
5 Selective O-deacylation and triflation was followed by treatment of the crude product with fluoride, then deprotection of the THP groups. Standard methodologies were used to obtain the 5'-DMT- and 5'-DMT-3'-phosphoramidites.

10 **2'-Fluorouridine**

Synthesis of 2'-deoxy-2'-fluorouridine was accomplished by the modification of a literature procedure in which 2,2'-anhydro-1-beta-D-arabinofuranosyluracil was treated with 70% hydrogen fluoride-pyridine. Standard procedures were used to
15 obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-Fluorodeoxycytidine

2'-deoxy-2'-fluorocytidine was synthesized via amination of 2'-deoxy-2'-fluorouridine, followed by selective
20 protection to give N4-benzoyl-2'-deoxy-2'-fluorocytidine. Standard procedures were used to obtain the 5'-DMT and 5'-DMT-3'phosphoramidites.

2'-O-(2-Methoxyethyl) modified amidites

25 2'-O-Methoxyethyl-substituted nucleoside amidites are prepared as follows, or alternatively, as per the methods of Martin, P., *Helvetica Chimica Acta*, 1995, 78, 486-504.

30 **2,2'-Anhydro[1-(beta-D-arabinofuranosyl)-5-methyluridine]**

5-Methyluridine (ribosylthymine, commercially available through Yamasa, Choshi, Japan) (72.0 g, 0.279 M), diphenylcarbonate (90.0 g, 0.420 M) and sodium bicarbonate (2.0 g,

0.024 M) were added to DMF (300 mL). The mixture was heated to reflux, with stirring, allowing the evolved carbon dioxide gas to be released in a controlled manner. After 1 hour, the slightly darkened solution was concentrated under reduced
5 pressure. The resulting syrup was poured into diethylether (2.5 L), with stirring. The product formed a gum. The ether was decanted and the residue was dissolved in a minimum amount of methanol (ca. 400 mL). The solution was poured into fresh ether (2.5 L) to yield a stiff gum. The ether was
10 decanted and the gum was dried in a vacuum oven (60°C at 1 mm Hg for 24 h) to give a solid that was crushed to a light tan powder (57 g, 85% crude yield). The NMR spectrum was consistent with the structure, contaminated with phenol as its sodium salt (ca. 5%). The material was used as is for
15 further reactions (or it can be purified further by column chromatography using a gradient of methanol in ethyl acetate (10-25%) to give a white solid, mp 222-4°C).

2'-O-Methoxyethyl-5-methyluridine

20 2,2'-Anhydro-5-methyluridine (195 g, 0.81 M), tris(2-methoxyethyl)borate (231 g, 0.98 M) and 2-methoxyethanol (1.2 L) were added to a 2 L stainless steel pressure vessel and placed in a pre-heated oil bath at 160°C. After heating for 48 hours at 155-160°C, the vessel was opened and the solution
25 evaporated to dryness and triturated with MeOH (200 mL). The residue was suspended in hot acetone (1 L). The insoluble salts were filtered, washed with acetone (150 mL) and the filtrate evaporated. The residue (280 g) was dissolved in CH₃CN (600 mL) and evaporated. A silica gel column (3 kg) was
30 packed in CH₂Cl₂/acetone/MeOH (20:5:3) containing 0.5% Et₃NH. The residue was dissolved in CH₂Cl₂ (250 mL) and adsorbed onto silica (150 g) prior to loading onto the column. The product was eluted with the packing solvent to give 160 g (63%) of

product. Additional material was obtained by reworking impure fractions.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine

5 2'-O-Methoxyethyl-5-methyluridine (160 g, 0.506 M) was co-evaporated with pyridine (250 mL) and the dried residue dissolved in pyridine (1.3 L). A first aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the mixture stirred at room temperature for one hour. A second
10 aliquot of dimethoxytrityl chloride (94.3 g, 0.278 M) was added and the reaction stirred for an additional one hour. Methanol (170 mL) was then added to stop the reaction. HPLC showed the presence of approximately 70% product. The solvent was evaporated and triturated with CH₃CN (200 mL).
15 The residue was dissolved in CHCl₃ (1.5 L) and extracted with 2x500 mL of saturated NaHCO₃ and 2x500 mL of saturated NaCl. The organic phase was dried over Na₂SO₄, filtered and evaporated. 275 g of residue was obtained. The residue was purified on a 3.5 kg silica gel column, packed and eluted
20 with EtOAc/hexane/acetone (5:5:1) containing 0.5% Et₃NH. The pure fractions were evaporated to give 164 g of product. Approximately 20 g additional was obtained from the impure fractions to give a total yield of 183 g (57%).

25 **3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (106 g, 0.167 M), DMF/pyridine (750 mL of a 3:1 mixture prepared from 562 mL of DMF and 188 mL of pyridine) and
30 acetic anhydride (24.38 mL, 0.258 M) were combined and stirred at room temperature for 24 hours. The reaction was monitored by TLC by first quenching the TLC sample with the addition of MeOH. Upon completion of the reaction, as judged

by TLC, MeOH (50 mL) was added and the mixture evaporated at 35°C. The residue was dissolved in CHCl₃ (800 mL) and extracted with 2x200 mL of saturated sodium bicarbonate and 2x200 mL of saturated NaCl. The water layers were back
5 extracted with 200 mL of CHCl₃. The combined organics were dried with sodium sulfate and evaporated to give 122 g of residue (approx. 90% product). The residue was purified on a 3.5 kg silica gel column and eluted using EtOAc/hexane(4:1). Pure product fractions were evaporated to yield 96 g (84%).
10 An additional 1.5 g was recovered from later fractions.

3'-O-Acetyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyl-4-triazoleuridine

A first solution was prepared by dissolving 3'-O-acetyl-
15 2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methyluridine (96 g, 0.144 M) in CH₃CN (700 mL) and set aside. Triethylamine (189 mL, 1.44 M) was added to a solution of triazole (90 g, 1.3 M) in CH₃CN (1 L), cooled to -5°C and stirred for 0.5 h using an overhead stirrer. POCl₃ was added dropwise, over a 30 minute
20 period, to the stirred solution maintained at 0-10°C, and the resulting mixture stirred for an additional 2 hours. The first solution was added dropwise, over a 45 minute period, to the latter solution. The resulting reaction mixture was stored overnight in a cold room. Salts were filtered from
25 the reaction mixture and the solution was evaporated. The residue was dissolved in EtOAc (1 L) and the insoluble solids were removed by filtration. The filtrate was washed with 1x300 mL of NaHCO₃ and 2x300 mL of saturated NaCl, dried over sodium sulfate and evaporated. The residue was triturated
30 with EtOAc to give the title compound.

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine

A solution of 3'-O-acetyl-2'-O-methoxyethyl-5'-O-

dimethoxytrityl-5-methyl-4-triazoleuridine (103 g, 0.141 M) in dioxane (500 mL) and NH_4OH (30 mL) was stirred at room temperature for 2 hours. The dioxane solution was evaporated and the residue azeotroped with MeOH (2x200 mL). The residue
5 was dissolved in MeOH (300 mL) and transferred to a 2 liter stainless steel pressure vessel. MeOH (400 mL) saturated with NH_3 gas was added and the vessel heated to 100°C for 2 hours (TLC showed complete conversion). The vessel contents were evaporated to dryness and the residue was dissolved in
10 EtOAc (500 mL) and washed once with saturated NaCl (200 mL). The organics were dried over sodium sulfate and the solvent was evaporated to give 85 g (95%) of the title compound.

15 **N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine**

2'-O-Methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (85 g, 0.134 M) was dissolved in DMF (800 mL) and benzoic anhydride (37.2 g, 0.165 M) was added with stirring. After stirring for 3 hours, TLC showed the reaction to be
20 approximately 95% complete. The solvent was evaporated and the residue azeotroped with MeOH (200 mL). The residue was dissolved in CHCl_3 (700 mL) and extracted with saturated NaHCO_3 (2x300 mL) and saturated NaCl (2x300 mL), dried over MgSO_4 and evaporated to give a residue (96 g). The residue
25 was chromatographed on a 1.5 kg silica column using EtOAc/hexane (1:1) containing 0.5% Et_3NH as the eluting solvent. The pure product fractions were evaporated to give 90 g (90%) of the title compound.

30 **N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine-3'-amidite**

N4-Benzoyl-2'-O-methoxyethyl-5'-O-dimethoxytrityl-5-methylcytidine (74 g, 0.10 M) was dissolved in CH_2Cl_2 (1 L).

Tetrazole diisopropylamine (7.1 g) and 2-cyanoethoxy-tetra-
(isopropyl)phosphite (40.5 mL, 0.123 M) were added with
stirring, under a nitrogen atmosphere. The resulting mixture
was stirred for 20 hours at room temperature (TLC showed the
5 reaction to be 95% complete). The reaction mixture was
extracted with saturated NaHCO_3 (1x300 mL) and saturated NaCl
(3x300 mL). The aqueous washes were back-extracted with
 CH_2Cl_2 (300 mL), and the extracts were combined, dried over
 MgSO_4 and concentrated. The residue obtained was
10 chromatographed on a 1.5 kg silica column using EtOAc/hexane
(3:1) as the eluting solvent. The pure fractions were
combined to give 90.6 g (87%) of the title compound.

2'-O-(Aminooxyethyl) nucleoside amidites and 2'-O-
15 (dimethylaminooxyethyl) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites

2'-(Dimethylaminooxyethoxy) nucleoside amidites [also
known in the art as 2'-O-(dimethylaminooxyethyl) nucleoside
amidites] are prepared as described in the following
20 paragraphs. Adenosine, cytidine and guanosine nucleoside
amidites are prepared similarly to the thymidine (5-
methyluridine) except the exocyclic amines are protected with
a benzoyl moiety in the case of adenosine and cytidine and
with isobutryl in the case of guanosine.

25

5'-O-tert-Butyldiphenylsilyl- O^2 -2'-anhydro-5-
methyluridine

O^2 -2'-anhydro-5-methyluridine (Pro. Bio. Sint., Varese,
Italy, 100.0g, 0.416 mmol), dimethylaminopyridine (0.66g,
30 0.013eq, 0.0054mmol) were dissolved in dry pyridine (500 ml)
at ambient temperature under an argon atmosphere and with
mechanical stirring. tert-Butyldiphenylchlorosilane (125.8g,
119.0mL, 1.1eq, 0.458mmol) was added in one portion. The

reaction was stirred for 16 h at ambient temperature. TLC (Rf 0.22, ethyl acetate) indicated a complete reaction. The solution was concentrated under reduced pressure to a thick oil. This was partitioned between dichloromethane (1 L) and saturated sodium bicarbonate (2x1 L) and brine (1 L). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to a thick oil. The oil was dissolved in a 1:1 mixture of ethyl acetate and ethyl ether (600mL) and the solution was cooled to -10°C. The resulting crystalline product was collected by filtration, washed with ethyl ether (3x200 mL) and dried (40°C, 1mm Hg, 24 h) to 149g (74.8%) of white solid. TLC and NMR were consistent with pure product.

15 **5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine**

In a 2 L stainless steel, unstirred pressure reactor was added borane in tetrahydrofuran (1.0 M, 2.0 eq, 622 mL). In the fume hood and with manual stirring, ethylene glycol (350 mL, excess) was added cautiously at first until the evolution of hydrogen gas subsided. 5'-O-tert-Butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine (149 g, 0.311 mol) and sodium bicarbonate (0.074 g, 0.003 eq) were added with manual stirring. The reactor was sealed and heated in an oil bath until an internal temperature of 160 °C was reached and then maintained for 16 h (pressure < 100 psig). The reaction vessel was cooled to ambient and opened. TLC (Rf 0.67 for desired product and Rf 0.82 for ara-T side product, ethyl acetate) indicated about 70% conversion to the product. In order to avoid additional side product formation, the reaction was stopped, concentrated under reduced pressure (10 to 1mm Hg) in a warm water bath (40-100°C) with the more extreme conditions used to remove the ethylene glycol.

[Alternatively, once the low boiling solvent is gone, the remaining solution can be partitioned between ethyl acetate and water. The product will be in the organic phase.] The residue was purified by column chromatography (2kg silica
5 gel, ethyl acetate-hexanes gradient 1:1 to 4:1). The appropriate fractions were combined, stripped and dried to product as a white crisp foam (84g, 50%), contaminated starting material (17.4g) and pure reusable starting material 20g. The yield based on starting material less pure
10 recovered starting material was 58%. TLC and NMR were consistent with 99% pure product.

2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine

15 5'-O-tert-Butyldiphenylsilyl-2'-O-(2-hydroxyethyl)-5-methyluridine (20g, 36.98mmol) was mixed with triphenylphosphine (11.63g, 44.36mmol) and N-hydroxyphthalimide (7.24g, 44.36mmol). It was then dried over P₂O₅ under high vacuum for two days at 40°C. The reaction
20 mixture was flushed with argon and dry THF (369.8mL, Aldrich, sure seal bottle) was added to get a clear solution. Diethyl-azodicarboxylate (6.98mL, 44.36mmol) was added dropwise to the reaction mixture. The rate of addition is maintained such that resulting deep red coloration is just
25 discharged before adding the next drop. After the addition was complete, the reaction was stirred for 4 hrs. By that time TLC showed the completion of the reaction (ethylacetate:hexane, 60:40). The solvent was evaporated in vacuum. Residue obtained was placed on a flash column and
30 eluted with ethyl acetate:hexane (60:40), to get 2'-O-([2-phthalimidoxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine as white foam (21.819 g, 86%).

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine

2'-O-([2-phthalimidooxy)ethyl]-5'-t-butyldiphenylsilyl-5-methyluridine (3.1g, 4.5mmol) was dissolved in dry CH₂Cl₂ (4.5mL) and methylhydrazine (300mL, 4.64mmol) was added dropwise at -10°C to 0°C. After 1 h the mixture was filtered, the filtrate was washed with ice cold CH₂Cl₂ and the combined organic phase was washed with water, brine and dried over anhydrous Na₂SO₄. The solution was concentrated to get 2'-O-(aminooxyethyl) thymidine, which was then dissolved in MeOH (67.5mL). To this formaldehyde (20% aqueous solution, w/w, 1.1 eq.) was added and the resulting mixture was stirred for 1 h. Solvent was removed under vacuum; residue chromatographed to get 5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy) ethyl]-5-methyluridine as white foam (1.95 g, 78%).

5'-O-tert-Butyldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine

5'-O-tert-butyldiphenylsilyl-2'-O-[(2-formadoximinooxy)ethyl]-5-methyluridine (1.77g, 3.12mmol) was dissolved in a solution of 1M pyridinium p-toluenesulfonate (PPTS) in dry MeOH (30.6mL). Sodium cyanoborohydride (0.39g, 6.13mmol) was added to this solution at 10°C under inert atmosphere. The reaction mixture was stirred for 10 minutes at 10°C. After that the reaction vessel was removed from the ice bath and stirred at room temperature for 2 h, the reaction monitored by TLC (5% MeOH in CH₂Cl₂). Aqueous NaHCO₃ solution (5%, 10mL) was added and extracted with ethyl acetate (2x20mL). Ethyl acetate phase was dried over anhydrous Na₂SO₄, evaporated to dryness. Residue was dissolved in a solution of 1M PPTS in MeOH (30.6mL). Formaldehyde (20% w/w, 30mL, 3.37mmol) was added and the

reaction mixture was stirred at room temperature for 10 minutes. Reaction mixture cooled to 10°C in an ice bath, sodium cyanoborohydride (0.39g, 6.13mmol) was added and reaction mixture stirred at 10°C for 10 minutes. After 10
5 minutes, the reaction mixture was removed from the ice bath and stirred at room temperature for 2 hrs. To the reaction mixture 5% NaHCO₃ (25mL) solution was added and extracted with ethyl acetate (2x25mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and evaporated to dryness. The residue
10 obtained was purified by flash column chromatography and eluted with 5% MeOH in CH₂Cl₂ to get 5'-O-tert-butylldiphenylsilyl-2'-O-[N,N-dimethylaminooxyethyl]-5-methyluridine as a white foam (14.6g, 80%).

15 **2'-O-(dimethylaminooxyethyl)-5-methyluridine**

Triethylamine trihydrofluoride (3.91mL, 24.0mmol) was dissolved in dry THF and triethylamine (1.67mL, 12mmol, dry, kept over KOH). This mixture of triethylamine-2HF was then added to 5'-O-tert-butylldiphenylsilyl-2'-O-[N,N-
20 dimethylaminooxyethyl]-5-methyluridine (1.40g, 2.4mmol) and stirred at room temperature for 24 hrs. Reaction was monitored by TLC (5% MeOH in CH₂Cl₂). Solvent was removed under vacuum and the residue placed on a flash column and eluted with 10% MeOH in CH₂Cl₂ to get 2'-O-
25 (dimethylaminooxyethyl)-5-methyluridine (766mg, 92.5%).

5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine

2'-O-(dimethylaminooxyethyl)-5-methyluridine (750mg, 2.17mmol) was dried over P₂O₅ under high vacuum overnight at
30 40°C. It was then co-evaporated with anhydrous pyridine (20mL). The residue obtained was dissolved in pyridine (11mL) under argon atmosphere. 4-dimethylaminopyridine (26.5mg, 2.60mmol), 4,4'-dimethoxytrityl chloride (880mg,

2.60mmol) was added to the mixture and the reaction mixture was stirred at room temperature until all of the starting material disappeared. Pyridine was removed under vacuum and the residue chromatographed and eluted with 10% MeOH in CH₂Cl₂,
5 (containing a few drops of pyridine) to get 5'-O-DMT-2'-O-(dimethylamino-oxyethyl)-5-methyluridine (1.13g, 80%).

5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite]
10 5'-O-DMT-2'-O-(dimethylaminooxyethyl)-5-methyluridine (1.08g, 1.67mmol) was co-evaporated with toluene (20mL). To the residue N,N-diisopropylamine tetrazonide (0.29g, 1.67mmol) was added and dried over P₂O₅ under high vacuum
15 overnight at 40°C. Then the reaction mixture was dissolved in anhydrous acetonitrile (8.4mL) and 2-cyanoethyl-N,N,N¹,N¹-tetraisopropylphosphoramidite (2.12mL, 6.08mmol) was added. The reaction mixture was stirred at ambient temperature for 4 hrs under inert atmosphere. The progress of the reaction was
20 monitored by TLC (hexane:ethyl acetate 1:1). The solvent was evaporated, then the residue was dissolved in ethyl acetate (70mL) and washed with 5% aqueous NaHCO₃ (40mL). Ethyl acetate layer was dried over anhydrous Na₂SO₄ and concentrated. Residue obtained was chromatographed (ethyl
25 acetate as eluent) to get 5'-O-DMT-2'-O-(2-N,N-dimethylaminooxyethyl)-5-methyluridine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite] as a foam (1.04g, 74.9%).

2'-(Aminooxyethoxy) nucleoside amidites

30 2'-(Aminooxyethoxy) nucleoside amidites [also known in the art as 2'-O-(aminooxyethyl) nucleoside amidites] are prepared as described in the following paragraphs. Adenosine, cytidine and thymidine nucleoside amidites are prepared

similarly.

N2-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-
5 [(2-cyanoethyl)-N,N-diisopropylphosphoramidite]

The 2'-O-aminooxyethyl guanosine analog may be obtained by selective 2'-O-alkylation of diaminopurine riboside. Multigram quantities of diaminopurine riboside may be purchased from Schering AG (Berlin) to provide 2'-O-(2-ethylacetyl) diaminopurine riboside along with a minor amount of the 3'-O-isomer. 2'-O-(2-ethylacetyl) diaminopurine riboside may be resolved and converted to 2'-O-(2-ethylacetyl)guanosine by treatment with adenosine deaminase. (McGee, D. P. C., Cook, P. D., Guinasso, C. J., WO 94/02501
15 A1 940203.) Standard protection procedures should afford 2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine and 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine which may be reduced to provide 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine. As before
20 the hydroxyl group may be displaced by N-hydroxyphthalimide via a Mitsunobu reaction, and the protected nucleoside may phosphitylated as usual to yield 2-N-isobutyryl-6-O-diphenylcarbamoyl-2'-O-(2-ethylacetyl)-5'-O-(4,4'-dimethoxytrityl)guanosine-3'-[(2-cyanoethyl)-N,N-diisopropylphosphoramidite].
25

2'-dimethylaminoethoxyethoxy (2'-DMAEOE) nucleoside amidites

2'-dimethylaminoethoxyethoxy nucleoside amidites (also
30 known in the art as 2'-O-dimethylaminoethoxyethyl, i.e., 2'-O-CH₂-O-CH₂-N(CH₂)₂, or 2'-DMAEOE nucleoside amidites) are prepared as follows. Other nucleoside amidites are prepared similarly.

2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

2[2-(Dimethylamino)ethoxy]ethanol (Aldrich, 6.66 g, 50 mmol) is slowly added to a solution of borane in tetrahydrofuran (1 M, 10 mL, 10 mmol) with stirring in a 100 mL bomb. Hydrogen gas evolves as the solid dissolves. O²-, 2'-anhydro-5-methyluridine (1.2 g, 5 mmol), and sodium bicarbonate (2.5 mg) are added and the bomb is sealed, placed in an oil bath and heated to 155°C for 26 hours. The bomb is cooled to room temperature and opened. The crude solution is concentrated and the residue partitioned between water (200 mL) and hexanes (200 mL). The excess phenol is extracted into the hexane layer. The aqueous layer is extracted with ethyl acetate (3x200 mL) and the combined organic layers are washed once with water, dried over anhydrous sodium sulfate and concentrated. The residue is columned on silica gel using methanol/methylene chloride 1:20 (which has 2% triethylamine) as the eluent. As the column fractions are concentrated a colorless solid forms which is collected to give the title compound as a white solid.

5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine

To 0.5 g (1.3 mmol) of 2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]-5-methyl uridine in anhydrous pyridine (8 mL), triethylamine (0.36 mL) and dimethoxytrityl chloride (DMT-Cl, 0.87 g, 2 eq.) are added and stirred for 1 hour. The reaction mixture is poured into water (200 mL) and extracted with CH₂Cl₂ (2x200 mL). The combined CH₂Cl₂ layers are washed with saturated NaHCO₃ solution, followed by saturated NaCl solution and dried over anhydrous sodium sulfate. Evaporation of the solvent followed by silica gel chromatography using MeOH:CH₂Cl₂:Et₃N (20:1, v/v, with 1% triethylamine) gives the title compound.

5'-O-Dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)-ethyl]]-5-methyl uridine-3'-O-(cyanoethyl-N,N-diisopropyl)phosphoramidite

Diisopropylaminotetrazolide (0.6 g) and 2-cyanoethoxy-
5 N,N-diisopropyl phosphoramidite (1.1 mL, 2 eq.) are added to
a solution of 5'-O-dimethoxytrityl-2'-O-[2(2-N,N-dimethylaminoethoxy)ethyl]]-5-methyluridine (2.17 g, 3 mmol)
dissolved in CH₂Cl₂ (20 mL) under an atmosphere of argon. The
reaction mixture is stirred overnight and the solvent
10 evaporated. The resulting residue is purified by silica gel
flash column chromatography with ethyl acetate as the eluent
to give the title compound.

Example 2

15 Oligonucleotide synthesis

Unsubstituted and substituted phosphodiester (P=O)
oligonucleotides are synthesized on an automated DNA
synthesizer (Applied Biosystems model 380B) using standard
phosphoramidite chemistry with oxidation by iodine.

20 Phosphorothioates (P=S) are synthesized as for the
phosphodiester oligonucleotides except the standard oxidation
bottle was replaced by 0.2 M solution of 3H-1,2-
benzodithiole-3-one 1,1-dioxide in acetonitrile for the
stepwise thiation of the phosphite linkages. The thiation
25 wait step was increased to 68 sec and was followed by the
capping step. After cleavage from the CPG column and
deblocking in concentrated ammonium hydroxide at 55°C (18 h),
the oligonucleotides were purified by precipitating twice
with 2.5 volumes of ethanol from a 0.5 M NaCl solution.
30 Phosphinate oligonucleotides are prepared as described in
U.S. Patent 5,508,270, herein incorporated by reference.

Alkyl phosphonate oligonucleotides are prepared as
described in U.S. Patent 4,469,863, herein incorporated by

reference.

3'-Deoxy-3'-methylene phosphonate oligonucleotides are prepared as described in U.S. Patents 5,610,289 or 5,625,050, herein incorporated by reference.

5 Phosphoramidite oligonucleotides are prepared as described in U.S. Patent, 5,256,775 or U.S. Patent 5,366,878, herein incorporated by reference.

Alkylphosphonothioate oligonucleotides are prepared as described in published PCT applications PCT/US94/00902 and
10 PCT/US93/06976 (published as WO 94/17093 and WO 94/02499, respectively), herein incorporated by reference.

3'-Deoxy-3'-amino phosphoramidate oligonucleotides are prepared as described in U.S. Patent 5,476,925, herein incorporated by reference.

15 Phosphotriester oligonucleotides are prepared as described in U.S. Patent 5,023,243, herein incorporated by reference.

Borano phosphate oligonucleotides are prepared as described in U.S. Patents 5,130,302 and 5,177,198, both
20 herein incorporated by reference.

Example 3

Oligonucleoside Synthesis

Methylenemethylimino linked oligonucleosides, also
25 identified as MMI linked oligonucleosides, methylenedimethylhydrazo linked oligonucleosides, also identified as MDH linked oligonucleosides, and methylenecarbonylamino linked oligonucleosides, also identified as amide-3 linked oligonucleosides, and methyleneaminocarbonyl linked oligo-
30 nucleosides, also identified as amide-4 linked oligonucleosides, as well as mixed backbone compounds having, for instance, alternating MMI and P=O or P=S linkages are prepared as described in U.S. Patents 5,378,825, 5,386,023,

5,489,677, 5,602,240 and 5,610,289, all of which are herein incorporated by reference.

Formacetal and thioformacetal linked oligonucleosides are prepared as described in U.S. Patents 5,264,562 and
5 5,264,564, herein incorporated by reference.

Ethylene oxide linked oligonucleosides are prepared as described in U.S. Patent 5,223,618, herein incorporated by reference.

Example 4

10 PNA Synthesis

Peptide nucleic acids (PNAs) are prepared in accordance with any of the various procedures referred to in Peptide Nucleic Acids (PNA): Synthesis, Properties and Potential Applications, *Bioorganic & Medicinal Chemistry*, 1996, 4, 5-
15 23. They may also be prepared in accordance with U.S. Patents 5,539,082, 5,700,922, and 5,719,262, herein incorporated by reference.

Example 5

Synthesis of Chimeric Oligonucleotides

20 Chimeric oligonucleotides, oligonucleosides or mixed oligonucleotides/oligonucleosides of the invention can be of several different types. These include a first type wherein the "gap" segment of linked nucleosides is positioned between 5' and 3' "wing" segments of linked nucleosides and a second
25 "open end" type wherein the "gap" segment is located at either the 3' or the 5' terminus of the oligomeric compound. Oligonucleotides of the first type are also known in the art as "gapmers" or gapped oligonucleotides. Oligonucleotides of the second type are also known in the art as "hemimers" or
30 "wingmers".

[2'-O-Me]--[2'-deoxy]--[2'-O-Me] Chimeric

Phosphorothioate Oligonucleotides

Chimeric oligonucleotides having 2'-O-alkyl

phosphorothioate and 2'-deoxy phosphorothioate oligonucleotide segments are synthesized using an Applied Biosystems automated DNA synthesizer Model 380B, as above. Oligonucleotides are synthesized using the automated
5 synthesizer and 2'-deoxy-5'-dimethoxytrityl-3'-O-phosphoramidite for the DNA portion and 5'-dimethoxytrityl-2'-O-methyl-3'-O-phosphoramidite for 5' and 3' wings. The standard synthesis cycle is modified by increasing the wait step after the delivery of tetrazole and base to 600 s
10 repeated four times for RNA and twice for 2'-O-methyl. The fully protected oligonucleotide is cleaved from the support and the phosphate group is deprotected in 3:1 ammonia/ethanol at room temperature overnight then lyophilized to dryness. Treatment in methanolic ammonia for 24 hrs at room
15 temperature is then done to deprotect all bases and sample was again lyophilized to dryness. The pellet is resuspended in 1M TBAF in THF for 24 hrs at room temperature to deprotect the 2' positions. The reaction is then quenched with 1M TEAA and the sample is then reduced to 1/2 volume by rotovac
20 before being desalted on a G25 size exclusion column. The oligo recovered is then analyzed spectrophotometrically for yield and for purity by capillary electrophoresis and by mass spectrometry.

25 [2'-O-(2-Methoxyethyl)]--[2'-deoxy]--[2'-O-(Methoxyethyl)] Chimeric Phosphorothioate Oligonucleotides

[2'-O-(2-methoxyethyl)]--[2'-deoxy]--[2'-O-(methoxyethyl)] chimeric phosphorothioate oligonucleotides were
30 prepared as per the procedure above for the 2'-O-methyl chimeric oligonucleotide, with the substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-methyl amidites.

[2'-O-(2-Methoxyethyl)Phosphodiester] -- [2'-deoxy
Phosphorothioate] -- [2'-O-(2-Methoxyethyl)
Phosphodiester] Chimeric Oligonucleotides

[2'-O-(2-methoxyethyl phosphodiester) -- [2'-deoxy phos-
5 phorothioate] -- [2'-O-(methoxyethyl) phosphodiester] chimeric
oligonucleotides are prepared as per the above procedure for
the 2'-O-methyl chimeric oligonucleotide with the
substitution of 2'-O-(methoxyethyl) amidites for the 2'-O-
methyl amidites, oxidization with iodine to generate the
10 phosphodiester internucleotide linkages within the wing
portions of the chimeric structures and sulfurization
utilizing 3,4-dihydro-2H-benzothiole-3-one 1,1 dioxide (Beaucage
Reagent) to generate the phosphorothioate internucleotide
linkages for the center gap.

15 Other chimeric oligonucleotides, chimeric oligonucleo-
sides and mixed chimeric oligonucleotides/oligonucleosides
are synthesized according to United States patent 5,623,065,
herein incorporated by reference.

20 Example 6

Oligonucleotide Isolation

After cleavage from the controlled pore glass column
(Applied Biosystems) and deblocking in concentrated ammonium
hydroxide at 55°C for 18 hours, the oligonucleotides or
25 oligonucleosides are purified by precipitation twice out of
0.5 M NaCl with 2.5 volumes ethanol. Synthesized
oligonucleotides were analyzed by polyacrylamide gel
electrophoresis on denaturing gels and judged to be at least
85% full length material. The relative amounts of
30 phosphorothioate and phosphodiester linkages obtained in
synthesis were periodically checked by ³¹P nuclear magnetic
resonance spectroscopy, and for some studies oligonucleotides
were purified by HPLC, as described by Chiang et al., J.

Biol. Chem. 1991, 266, 18162-18171. Results obtained with HPLC-purified material were similar to those obtained with non-HPLC purified material.

5 **Example 7**

Oligonucleotide Synthesis - 96 Well Plate Format

Oligonucleotides were synthesized via solid phase P(III) phosphoramidite chemistry on an automated synthesizer capable of assembling 96 sequences simultaneously in a standard 96
10 well format. Phosphodiester internucleotide linkages were afforded by oxidation with aqueous iodine. Phosphorothioate internucleotide linkages were generated by sulfurization utilizing 3,4-dihydro-2H-benzothio-3-one 1,1 dioxide (Beaucage Reagent) in anhydrous acetonitrile. Standard base-protected
15 beta-cyanoethyl-diisopropyl phosphoramidites were purchased from commercial vendors (e.g. PE-Applied Biosystems, Foster City, CA, or Pharmacia, Piscataway, NJ). Non-standard nucleosides are synthesized as per known literature or patented methods. They are utilized as base protected beta-
20 cyanoethyl-diisopropyl phosphoramidites.

Oligonucleotides were cleaved from support and deprotected with concentrated NH_4OH at elevated temperature (55-60°C) for 12-16 hours and the released product then dried in vacuo. The dried product was then re-suspended in sterile
25 water to afford a master plate from which all analytical and test plate samples are then diluted utilizing robotic pipettors.

Example 8

30 **Oligonucleotide Analysis - 96 Well Plate Format**

The concentration of oligonucleotide in each well was assessed by dilution of samples and UV absorption spectroscopy. The full-length integrity of the individual

products was evaluated by capillary electrophoresis (CE) in either the 96 well format (Beckman P/ACE™ MDQ) or, for individually prepared samples, on a commercial CE apparatus (e.g., Beckman P/ACE™ 5000, ABI 270). Base and backbone composition was confirmed by mass analysis of the compounds utilizing electrospray-mass spectroscopy. All assay test plates were diluted from the master plate using single and multi-channel robotic pipettors. Plates were judged to be acceptable if at least 85% of the compounds on the plate were at least 85% full length.

Example 9

Cell culture and oligonucleotide treatment

The effect of antisense compounds on target nucleic acid expression can be tested in any of a variety of cell types provided that the target nucleic acid is present at measurable levels. This can be routinely determined using, for example, PCR or Northern blot analysis. The following 4 cell types are provided for illustrative purposes, but other cell types can be routinely used, provided that the target is expressed in the cell type chosen. This can be readily determined by methods routine in the art, for example Northern blot analysis, Ribonuclease protection assays, or RT-PCR.

25

T-24 cells:

The transitional cell bladder carcinoma cell line T-24 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). T-24 cells were routinely cultured in complete McCoy's 5A basal media (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL

(Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and dilution when they reached 90% confluence. Cells were seeded into 96-well plates (Falcon-Primaria #3872) at a density of 7000

5 cells/well for use in RT-PCR analysis.

For Northern blotting or other analysis, cells may be seeded onto 100 mm or other standard tissue culture plates and treated similarly, using appropriate volumes of medium and oligonucleotide.

10

A549 cells:

The human lung carcinoma cell line A549 was obtained from the American Type Culture Collection (ATCC) (Manassas, VA). A549 cells were routinely cultured in DMEM basal media
15 (Gibco/Life Technologies, Gaithersburg, MD) supplemented with 10% fetal calf serum (Gibco/Life Technologies, Gaithersburg, MD), penicillin 100 units per mL, and streptomycin 100 micrograms per mL (Gibco/Life Technologies, Gaithersburg, MD). Cells were routinely passaged by trypsinization and
20 dilution when they reached 90% confluence.

NHDF cells:

Human neonatal dermal fibroblast (NHDF) were obtained from the Clonetics Corporation (Walkersville MD). NHDFs were
25 routinely maintained in Fibroblast Growth Medium (Clonetics Corporation, Walkersville MD) supplemented as recommended by the supplier. Cells were maintained for up to 10 passages as recommended by the supplier.

30 HEK cells:

Human embryonic keratinocytes (HEK) were obtained from the Clonetics Corporation (Walkersville MD). HEKs were routinely maintained in Keratinocyte Growth Medium (Clonetics

Corporation, Walkersville MD) formulated as recommended by the supplier. Cells were routinely maintained for up to 10 passages as recommended by the supplier.

5 Treatment with antisense compounds:

When cells reached 80% confluency, they were treated with oligonucleotide. For cells grown in 96-well plates, wells were washed once with 200 μ L OPTI-MEM™-1 reduced-serum medium (Gibco BRL) and then treated with 130 μ L of OPTI-MEM™-10 1 containing 3.75 μ g/mL LIPOFECTIN™ (Gibco BRL) and the desired concentration of oligonucleotide. After 4-7 hours of treatment, the medium was replaced with fresh medium. Cells were harvested 16-24 hours after oligonucleotide treatment.

The concentration of oligonucleotide used varies from 15 cell line to cell line. To determine the optimal oligonucleotide concentration for a particular cell line, the cells are treated with a positive control oligonucleotide at a range of concentrations. For human cells the positive control oligonucleotide is ISIS 13920, **TCCGTCATCGCTCCTCAGGG**, 20 SEQ ID NO: 1, a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to human H-ras. For mouse or rat cells the positive control oligonucleotide is ISIS 15770, **ATGCATTCTGCCCCAAGGA**, 25 SEQ ID NO: 2; a 2'-O-methoxyethyl gapmer (2'-O-methoxyethyls shown in bold) with a phosphorothioate backbone which is targeted to both mouse and rat c-raf. The concentration of positive control oligonucleotide that results in 80% inhibition of c-Ha-ras (for ISIS 13920) or c-raf (for ISIS 15770) mRNA is then utilized as the screening concentration 30 for new oligonucleotides in subsequent experiments for that cell line. If 80% inhibition is not achieved, the lowest concentration of positive control oligonucleotide that results in 60% inhibition of H-ras or c-raf mRNA is then

utilized as the oligonucleotide screening concentration in subsequent experiments for that cell line. If 60% inhibition is not achieved, that particular cell line is deemed as unsuitable for oligonucleotide transfection experiments.

5

Example 10

Analysis of oligonucleotide inhibition of glycogen synthase kinase 3 beta expression

Antisense modulation of glycogen synthase kinase 3 beta
10 expression can be assayed in a variety of ways known in the art. For example, glycogen synthase kinase 3 beta mRNA levels can be quantitated by, e.g., Northern blot analysis, competitive polymerase chain reaction (PCR), or real-time PCR (RT-PCR). Real-time quantitative PCR is presently preferred.
15 RNA analysis can be performed on total cellular RNA or poly(A)+ mRNA. Methods of RNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.1.1-4.2.9 and 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Northern blot analysis is routine
20 in the art and is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.2.1-4.2.9, John Wiley & Sons, Inc., 1996. Real-time quantitative (PCR) can be conveniently accomplished using the commercially available ABI PRISM™ 7700 Sequence Detection
25 System, available from PE-Applied Biosystems, Foster City, CA and used according to manufacturer's instructions. Prior to quantitative PCR analysis, primer-probe sets specific to the target gene being measured are evaluated for their ability to be "multiplexed" with a GAPDH amplification reaction. In
30 multiplexing, both the target gene and the internal standard gene GAPDH are amplified concurrently in a single sample. In this analysis, mRNA isolated from untreated cells is serially diluted. Each dilution is amplified in the presence of

primer-probe sets specific for GAPDH only, target gene only ("single-plexing"), or both (multiplexing). Following PCR amplification, standard curves of GAPDH and target mRNA signal as a function of dilution are generated from both the single-plexed and multiplexed samples. If both the slope and correlation coefficient of the GAPDH and target signals generated from the multiplexed samples fall within 10% of their corresponding values generated from the single-plexed samples, the primer-probe set specific for that target is deemed as multiplexable. Other methods of PCR are also known in the art.

Protein levels of glycogen synthase kinase 3 beta can be quantitated in a variety of ways well known in the art, such as immunoprecipitation, Western blot analysis (immunoblotting), ELISA or fluorescence-activated cell sorting (FACS). Antibodies directed to glycogen synthase kinase 3 beta can be identified and obtained from a variety of sources, such as the MSRS catalog of antibodies (Aerie Corporation, Birmingham, MI), or can be prepared via conventional antibody generation methods. Methods for preparation of polyclonal antisera are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.12.1-11.12.9, John Wiley & Sons, Inc., 1997. Preparation of monoclonal antibodies is taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 11.4.1-11.11.5, John Wiley & Sons, Inc., 1997.

Immunoprecipitation methods are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 2, pp. 10.16.1-10.16.11, John Wiley & Sons, Inc., 1998. Western blot (immunoblot) analysis is standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in*

Molecular Biology, Volume 2, pp. 10.8.1-10.8.21, John Wiley & Sons, Inc., 1997. Enzyme-linked immunosorbent assays (ELISA) are standard in the art and can be found at, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*,
5 Volume 2, pp. 11.2.1-11.2.22, John Wiley & Sons, Inc., 1991.

Example 11

Poly(A)+ mRNA isolation

Poly(A)+ mRNA was isolated according to Miura et al.,
10 *Clin. Chem.*, 1996, 42, 1758-1764. Other methods for poly(A)+ mRNA isolation are taught in, for example, Ausubel, F.M. et al., *Current Protocols in Molecular Biology*, Volume 1, pp. 4.5.1-4.5.3, John Wiley & Sons, Inc., 1993. Briefly, for cells grown on 96-well plates, growth medium was removed from
15 the cells and each well was washed with 200 μ L cold PBS. 60 μ L lysis buffer (10 mM Tris-HCl, pH 7.6, 1 mM EDTA, 0.5 M NaCl, 0.5% NP-40, 20 mM vanadyl-ribonucleoside complex) was added to each well, the plate was gently agitated and then incubated at room temperature for five minutes. 55 μ L of
20 lysate was transferred to Oligo d(T) coated 96-well plates (AGCT Inc., Irvine CA). Plates were incubated for 60 minutes at room temperature, washed 3 times with 200 μ L of wash buffer (10 mM Tris-HCl pH 7.6, 1 mM EDTA, 0.3 M NaCl). After the final wash, the plate was blotted on paper towels to
25 remove excess wash buffer and then air-dried for 5 minutes. 60 μ L of elution buffer (5 mM Tris-HCl pH 7.6), preheated to 70°C was added to each well, the plate was incubated on a 90°C hot plate for 5 minutes, and the eluate was then transferred to a fresh 96-well plate.
30 Cells grown on 100 mm or other standard plates may be treated similarly, using appropriate volumes of all solutions.

Example 12

Total RNA Isolation

Total mRNA was isolated using an RNEASY 96™ kit and buffers purchased from Qiagen Inc. (Valencia CA) following the manufacturer's recommended procedures. Briefly, for cells grown on 96-well plates, growth medium was removed from the cells and each well was washed with 200 μ L cold PBS. 100 μ L Buffer RLT was added to each well and the plate vigorously agitated for 20 seconds. 100 μ L of 70% ethanol was then added to each well and the contents mixed by pipetting three times up and down. The samples were then transferred to the RNEASY 96™ well plate attached to a QIAVAC™ manifold fitted with a waste collection tray and attached to a vacuum source. Vacuum was applied for 15 seconds. 1 mL of Buffer RW1 was added to each well of the RNEASY 96™ plate and the vacuum again applied for 15 seconds. 1 mL of Buffer RPE was then added to each well of the RNEASY 96™ plate and the vacuum applied for a period of 15 seconds. The Buffer RPE wash was then repeated and the vacuum was applied for an additional 10 minutes. The plate was then removed from the QIAVAC™ manifold and blotted dry on paper towels. The plate was then re-attached to the QIAVAC™ manifold fitted with a collection tube rack containing 1.2 mL collection tubes. RNA was then eluted by pipetting 60 μ L water into each well, incubating 1 minute, and then applying the vacuum for 30 seconds. The elution step was repeated with an additional 60 μ L water.

The repetitive pipetting and elution steps may be automated using a QIAGEN Bio-Robot 9604 (Qiagen, Inc., Valencia CA). Essentially, after lysing of the cells on the culture plate, the plate is transferred to the robot deck where the pipetting, DNase treatment and elution steps are carried out.

Example 13

Real-time Quantitative PCR Analysis of glycogen synthase kinase 3 beta mRNA Levels

Quantitation of glycogen synthase kinase 3 beta mRNA
5 levels was determined by real-time quantitative PCR using the
ABI PRISM™ 7700 Sequence Detection System (PE-Applied
Biosystems, Foster City, CA) according to manufacturer's
instructions. This is a closed-tube, non-gel-based,
fluorescence detection system which allows high-throughput
10 quantitation of polymerase chain reaction (PCR) products in
real-time. As opposed to standard PCR, in which
amplification products are quantitated after the PCR is
completed, products in real-time quantitative PCR are
quantitated as they accumulate. This is accomplished by
15 including in the PCR reaction an oligonucleotide probe that
anneals specifically between the forward and reverse PCR
primers, and contains two fluorescent dyes. A reporter dye
(e.g., JOE, FAM, or VIC, obtained from either Operon
Technologies Inc., Alameda, CA or PE-Applied Biosystems,
20 Foster City, CA) is attached to the 5' end of the probe and a
quencher dye (e.g., TAMRA, obtained from either Operon
Technologies Inc., Alameda, CA or PE-Applied Biosystems,
Foster City, CA) is attached to the 3' end of the probe.
When the probe and dyes are intact, reporter dye emission is
25 quenched by the proximity of the 3' quencher dye. During
amplification, annealing of the probe to the target sequence
creates a substrate that can be cleaved by the 5'-exonuclease
activity of Taq polymerase. During the extension phase of
the PCR amplification cycle, cleavage of the probe by Taq
30 polymerase releases the reporter dye from the remainder of
the probe (and hence from the quencher moiety) and a
sequence-specific fluorescent signal is generated. With each
cycle, additional reporter dye molecules are cleaved from

their respective probes, and the fluorescence intensity is monitored at regular intervals by laser optics built into the ABI PRISM™ 7700 Sequence Detection System. In each assay, a series of parallel reactions containing serial dilutions of mRNA from untreated control samples generates a standard curve that is used to quantitate the percent inhibition after antisense oligonucleotide treatment of test samples.

PCR reagents were obtained from PE-Applied Biosystems, Foster City, CA. RT-PCR reactions were carried out by adding 25 μ L PCR cocktail (1x TAQMAN™ buffer A, 5.5 mM MgCl₂, 300 μ M each of dATP, dCTP and dGTP, 600 μ M of dUTP, 100 nM each of forward primer, reverse primer, and probe, 20 Units RNase inhibitor, 1.25 Units AMPLITAQ GOLD™, and 12.5 Units MuLV reverse transcriptase) to 96 well plates containing 25 μ L poly(A) mRNA solution. The RT reaction was carried out by incubation for 30 minutes at 48°C. Following a 10 minute incubation at 95°C to activate the AMPLITAQ GOLD™, 40 cycles of a two-step PCR protocol were carried out: 95°C for 15 seconds (denaturation) followed by 60°C for 1.5 minutes (annealing/extension).

Probes and primers to human glycogen synthase kinase 3 beta were designed to hybridize to a human glycogen synthase kinase 3 beta sequence, using published sequence information (GenBank accession number L33801, incorporated herein as SEQ ID NO:3). For human glycogen synthase kinase 3 beta the PCR primers were:

forward primer: TTCAGCTTTTGGCAGCATGA (SEQ ID NO: 4)

reverse primer: GAGTTGCCACCACTGTTGTCA (SEQ ID NO: 5) and the

PCR probe was: FAM-CTTGCTGCCGTCCTTGTCTCTGCTAACT-TAMRA

(SEQ ID NO: 6) where FAM (PE-Applied Biosystems, Foster City, CA) is the fluorescent reporter dye) and TAMRA (PE-Applied Biosystems, Foster City, CA) is the quencher dye. For human GAPDH the PCR primers were:

forward primer: GAAGGTGAAGGTCGGAGTC (SEQ ID NO: 7)
reverse primer: GAAGATGGTGATGGGATTTC (SEQ ID NO: 8) and the
PCR probe was: 5' JOE-CAAGCTTCCCGTTCTCAGCC- TAMRA 3' (SEQ ID
NO: 9) where JOE (PE-Applied Biosystems, Foster City, CA) is
5 the fluorescent reporter dye) and TAMRA (PE-Applied
Biosystems, Foster City, CA) is the quencher dye.

Example 14

10 Northern blot analysis of glycogen synthase kinase 3 beta mRNA levels

Eighteen hours after antisense treatment, cell
monolayers were washed twice with cold PBS and lysed in 1 mL
RNAZOL™ (TEL-TEST "B" Inc., Friendswood, TX). Total RNA was
15 prepared following manufacturer's recommended protocols.
Twenty micrograms of total RNA was fractionated by
electrophoresis through 1.2% agarose gels containing 1.1%
formaldehyde using a MOPS buffer system (AMRESCO, Inc. Solon,
OH). RNA was transferred from the gel to HYBOND™-N+ nylon
20 membranes (Amersham Pharmacia Biotech, Piscataway, NJ) by
overnight capillary transfer using a Northern/Southern
Transfer buffer system (TEL-TEST "B" Inc., Friendswood, TX).
RNA transfer was confirmed by UV visualization. Membranes
were fixed by UV cross-linking using a STRATALINKER™ UV
25 Crosslinker 2400 (Stratagene, Inc, La Jolla, CA) and then
robed using QUICKHYB™ hybridization solution (Stratagene, La
Jolla, CA) using manufacturer's recommendations for stringent
conditions.

To detect human glycogen synthase kinase 3 beta, a human
30 glycogen synthase kinase 3 beta specific probe was prepared
by PCR using the forward primer TTCAGCTTTTGGCAGCATGA (SEQ ID
NO: 4) and the reverse primer GAGTTGCCACCACTGTTGTCA (SEQ ID
NO: 5). To normalize for variations in loading and transfer

efficiency membranes were stripped and probed for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA (Clontech, Palo Alto, CA).

Hybridized membranes were visualized and quantitated using a PHOSPHORIMAGER™ and IMAGEQUANT™ Software V3.3 (Molecular Dynamics, Sunnyvale, CA). Data was normalized to GAPDH levels in untreated controls.

10 Example 15

Antisense inhibition of human glycogen synthase kinase 3 beta expression by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

In accordance with the present invention, a series of oligonucleotides were designed to target different regions of the human glycogen synthase kinase 3 beta RNA, using published sequences (GenBank accession number L33801, incorporated herein as SEQ ID NO: 3, and GenBank accession number AA132666, incorporated herein as SEQ ID NO: 10). The oligonucleotides are shown in Table 1. "Target site" indicates the first (5'-most) nucleotide number on the particular target sequence to which the oligonucleotide binds. All compounds in Table 1 are chimeric oligonucleotides ("gapmers") 20 nucleotides in length, composed of a central "gap" region consisting of ten 2'-deoxynucleotides, which is flanked on both sides (5' and 3' directions) by five-nucleotide "wings". The wings are composed of 2'-methoxyethyl (2'-MOE)nucleotides. The internucleoside (backbone) linkages are phosphorothioate (P=S) throughout the oligonucleotide. All cytidine residues are 5-methylcytidines. The compounds were analyzed for their effect on human glycogen synthase kinase 3 beta mRNA levels by quantitative real-time PCR as described in other examples

herein. Data are averages from two experiments. If present, "N.D." indicates "no data".

Table 1

5 Inhibition of human glycogen synthase kinase 3 beta mRNA levels by chimeric phosphorothioate oligonucleotides having 2'-MOE wings and a deoxy gap

	ISIS #	REGION	TARGET SEQ ID NO	TARGET SITE	SEQUENCE	%INHIB	SEQ ID NO
10	117428	Coding	3	60	agctctccgcaaaggaggtg	75	11
	117429	Coding	3	65	cttgagctctccgcaaagg	67	12
	117430	Coding	3	70	accggcttgagctctccgc		13
	117431	Coding	3	88	aaagctgaaggctgctgcac	17	14
	117432	Coding	3	106	ctaactttcatgctgcaaaa	88	15
15	117433	Coding	3	112	tctctgctaactttcatgct	91	16
	117434	Coding	3	123	tgccgtccttgtctctgcta	98	17
	117435	Coding	3	154	ccaggagttgccaccactgt	88	18
	117436	Coding	3	224	accaaagatccatttccaa	75	19
	117437	Coding	3	235	tgatataccacaccaaata	72	20
20	117438	Coding	3	240	tggcttgatataccacacca	95	21
	117439	Coding	3	245	aagtttggttgatatacca	51	22
	117440	Coding	3	250	tcacaaagtttggttgata	79	23
	117441	Coding	3	294	tcttgctcgaataactttc	49	24
	117442	Coding	3	326	tctcatgatctggagctctc	85	25
25	117443	Coding	3	331	agctttctcatgatctggag	76	26
	117444	Coding	3	341	acagtgatctagctttctca	74	27
	117445	Coding	3	351	ggactatgttacagtgatct	80	28
	117446	Coding	3	366	agaaataacgcaatcggact	70	29
	117447	Coding	3	396	cctcatctttcttctcacca	54	30
30	117448	Coding	3	400	tagacctcatctttcttctc	57	31
	117449	Coding	3	404	aagatagacctcatctttct	63	32
	117450	Coding	3	428	cggacatagtcagcacca	83	33
	117451	Coding	3	436	actgtttccggaacatagtc	53	34
	117452	Coding	3	445	actctgtatactgtttccgg	70	35
35	117453	Coding	3	456	agtgtctggcaactctgtat	56	36
	117454	Coding	3	463	cgactatagtgctggcaac	84	37
	117455	Coding	3	466	gctcgactatagtgctggc	52	38
	117456	Coding	3	476	cgtctgtttggctcgactat	58	39
	117457	Coding	3	509	atacatatacaacttgacat	54	40
40	117458	Coding	3	535	atataggctaaacttcggaa	55	41
	117459	Coding	3	545	aaaggaatggatataggcta	87	42
	117460	Coding	3	564	tatcccgatggcagattcca	76	43
	117461	Coding	3	592	ggatccaacaagaggttctg	80	44
	117462	Coding	3	619	tcacagagttttaatacagc	52	45
45	117463	Coding	3	639	gctgctttgcaactccaaag	64	46
	117464	Coding	3	676	gaacagatatacgaaacatt	45	47
	117465	Coding	3	695	tggtgccctatagtaccgag	69	48
	117466	Coding	3	704	gatcaactctggtgccctat	71	49

	117467	Coding	3	706	aagatcaactctggtgccct	80	50
	117468	Coding	3	745	gaccatacatctatactaga	27	51
	117469	Coding	3	748	gcagaccatacatctatact	75	52
	117470	Coding	3	783	gttgtccttagtaacagctca	66	53
5	117471	Coding	3	793	ggaaatattggttgtcctag	63	54
	117472	Coding	3	820	accaactgatccacaccact	67	55
	117473	Coding	3	874	ttcattttctctgatttgctc	57	56
	117474	Coding	3	880	tttgggttcattttctctgat	7	57
	117475	Coding	3	963	caattgcctccggtggagtt	38	58
10	117476	Coding	3	1002	gggcagttggtgtatactcc	17	59
	117477	Coding	3	1024	caagcttccagtggtgtag	47	60
	117478	Coding	3	1029	gtgcacaagcttccagtgg	29	61
	117479	Coding	3	1034	tgaatgtgcacaagcttcca	63	62
	117480	Coding	3	1039	aaaaatgaatgtgcacaagc	69	63
15	117481	Coding	3	1049	taattcatcaaaaaatgaat	6	64
	117482	Coding	3	1059	ttgggtcccgtaatcatca	25	65
	117483	Coding	3	1077	catttggatgtttgacattt	26	66
	117484	Coding	3	1090	ggtgtgtctcgccatttgg	48	67
	117485	Coding	3	1094	tgcaggtgtgtctcgccat	76	68
20	117486	Coding	3	1102	ttgaagagtgcaggtgtgtc	35	69
	117487	Coding	3	1126	cttgacagttcttgagtgg	54	70
	117488	Coding	3	1155	gaataaggatggtagccaga	65	71
	117489	Coding	3	1169	ccgagcatgaggaggaataa	35	72
	117490	Coding	3	1184	agcagctgcttgaatccgag	10	73
25	117491	Coding	3	1244	ggtctgtccacggtctccag	66	74
	117492	Coding	3	1249	ttattggtctgtccacggtc	65	75
	117493	Coding	3	1273	ttggaagctgatgcagaagc	51	76
	117494	Stop	3	1292	cgggactgttcaggtggagt	17	77
		Codon					
	117495	3' UTR	3	1327	agtaactgggtggtttttcct	32	78
30	117496	3' UTR	3	1342	gctgagtgcactcaagtaa	80	79
	117497	3' UTR	3	1354	gtgaccagtgttgctgagt	71	80
	117498	3' UTR	3	1356	acgtgaccagtgttgctgag	59	81
	117499	3' UTR	3	1359	caaacgtgaccagtgttgct	59	82
	117500	3' UTR	3	1364	ctttccaaacgtgaccagt	49	83
35	117501	5' UTR	10	21	gttaggttaacgataaatgc	75	84
	117502	5' UTR	10	51	cttttcttccttttgtcttt	72	85

As shown in Table 1, SEQ ID NOs 11, 12, 15, 16, 17, 18,
 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48,
 49, 50, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 63, 65, 66,
 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83,
 84 and 85 demonstrated at least 20% inhibition of human
 glycogen synthase kinase 3 beta expression in this assay and
 are therefore preferred.

Example 16

Western blot analysis of glycogen synthase kinase 3 beta

5 protein levels

Western blot analysis (immunoblot analysis) is carried out using standard methods. Cells are harvested 16-20 h after oligonucleotide treatment, washed once with PBS, suspended in Laemmli buffer (100 μ l/well), boiled for 5
10 minutes and loaded on a 16% SDS-PAGE gel. Gels are run for 1.5 hours at 150 V, and transferred to membrane for western blotting. Appropriate primary antibody directed to glycogen synthase kinase 3 beta is used, with a radiolabelled or fluorescently labeled secondary antibody directed against the
15 primary antibody species. Bands are visualized using a PHOSPHORIMAGER™ (Molecular Dynamics, Sunnyvale CA).

What is claimed is:

1. An antisense compound 8 to 30 nucleobases in length targeted to a nucleic acid molecule encoding glycogen synthase kinase 3 beta, wherein said antisense compound specifically hybridizes with and inhibits the expression of glycogen synthase kinase 3 beta.

2. The antisense compound of claim 1 which is an antisense oligonucleotide.

10 3. The antisense compound of claim 2 wherein the antisense oligonucleotide has a sequence comprising SEQ ID NO: 11, 12, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 58, 60, 61, 62, 15 63, 65, 66, 67, 68, 69, 70, 71, 72, 74, 75, 76, 78, 79, 80, 81, 82, 83, 84 or 85.

4. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.

20 5. The antisense compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.

6. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.

25 7. The antisense compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.

8. The antisense compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

30 9. The antisense compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

10. The antisense compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.

11. A composition comprising the antisense compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

12. The composition of claim 11 further comprising a colloidal dispersion system.

5 13. The composition of claim 11 wherein the antisense compound is an antisense oligonucleotide.

14. A method of inhibiting the expression of glycogen synthase kinase 3 beta in cells or tissues comprising contacting said cells or tissues with the antisense compound of claim 1 so
10 that expression of glycogen synthase kinase 3 beta is inhibited.

15. A method of treating a human having a disease or condition associated with glycogen synthase kinase 3 beta comprising administering to said animal a therapeutically or prophylactically effective amount of the antisense compound of
15 claim 1 so that expression of glycogen synthase kinase 3 beta is inhibited.

16. The method of claim 15 wherein the disease or condition is an insulin regulation disorder.

17. The method of claim 16 wherein the insulin regulation
20 disorder is diabetes.

18. The method of claim 15 wherein the disease or condition is a neurological disorder.

19. The method of claim 18 wherein the neurological disorder is Alzheimer's disease.

25 20. The method of claim 15 wherein the neurological disorder is bipolar illness.

<110> Isis Pharmaceuticals, Inc.
 Madeline M. Butler
 Robert McKay
 Brett P. Monia
 Jacqueline Wyatt

<120> ANTISENSE MODULATION OF GLYCOGEN SYNTHASE KINASE 3 BETA
 EXPRESSION

<130> RTSP-0091

<150> 09/489,765

<151> 2000-01-19

<160> 85

<210> 1

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 1

tccgctcatcg ctccctcaggg

20

<210> 2

<211> 20

<212> DNA

<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 2

atgcattctg cccccaagga

20

<210> 3

<211> 1389

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (40)...(1302)

<400> 3

ggagaaggaa ggaaaagggtg attcgcggaag agagtgatc atg tca ggg cgg ccc
 Met Ser Gly Arg Pro
 1 5

54

aga acc acc tcc ttt gcg gag agc tgc aag ccg gtg cag cag cct tca
 Arg Thr Thr Ser Phe Ala Glu Ser Cys Lys Pro Val Gln Gln Pro Ser
 10 15 20

102

gct ttt ggc agc atg aaa gtt agc aga gac aag gac ggc agc aag gtg
 Ala Phe Gly Ser Met Lys Val Ser Arg Asp Lys Asp Gly Ser Lys Val
 25 30 35

150

aca aca gtg gtg gca act cct ggg cag ggt cca gac agg cca caa gaa
 Thr Thr Val Ala Thr Pro Gly Gln Gly Pro Asp Arg Pro Gln Glu
 40 45 50

198

gtc agc tat aca gac act aaa gtg att gga aat gga tca ttt ggt gtg	246
Val Ser Tyr Thr Asp Thr Lys Val Ile Gly Asn Gly Ser Phe Gly Val	
55 60 65	
gta tat caa gcc aaa ctt tgt gat tca gga gaa ctg gtc gcc atc aag	294
Val Tyr Gln Ala Lys Leu Cys Asp Ser Gly Glu Leu Val Ala Ile Lys	
70 75 80 85	
aaa gta ttg cag gac aag aga ttt aag aat cga gag ctg cag atc atg	342
Lys Val Leu Gln Asp Lys Arg Phe Lys Asn Arg Glu Leu Gln Ile Met	
90 95 100	
aga aag cta gat cac tgt aac ata gtc cga ttg cgt tat ttc ttc tac	390
Arg Lys Leu Asp His Cys Asn Ile Val Arg Leu Arg Tyr Phe Phe Tyr	
105 110 115	
tcc agt ggt gag aag aaa gat gag gtc tat ctt aat ctg gtg ctg gac	438
Ser Ser Gly Glu Lys Lys Asp Glu Val Tyr Leu Asn Leu Val Leu Asp	
120 125 130	
tat gtt ccg gaa aca gta tac aga gtt gcc aga cac tat agt cga gcc	486
Tyr Val Pro Glu Thr Val Tyr Arg Val Ala Arg His Tyr Ser Arg Ala	
135 140 145	
aaa cag acg ctg cct gtg att tat gtc aag ttg tat atg tat cag ctg	534
Lys Gln Thr Leu Pro Val Ile Tyr Val Lys Leu Tyr Met Tyr Gln Leu	
150 155 160 165	
ttc cga agt tta gcc tat atc cat tcc ttt gga atc tgc cat cgg gat	582
Phe Arg Ser Leu Ala Tyr Ile His Ser Phe Gly Ile Cys His Arg Asp	
170 175 180	
att aaa ccg cag aac ctg ttg ttg gat cct gat act gct gta tta aaa	630
Ile Lys Pro Gln Asn Leu Leu Leu Asp Pro Asp Thr Ala Val Leu Lys	
185 190 195	
ctc tgt gac ttt gga agt gca aag cag ctg gtc cga gga gaa ccc aat	678
Leu Cys Asp Phe Gly Ser Ala Lys Gln Leu Val Arg Gly Glu Pro Asn	
200 205 210	
gtt tcg tat atc tgt tct cgg tac tat agg gca cca gag ttg atc ttt	726
Val Ser Tyr Ile Cys Ser Arg Tyr Tyr Arg Ala Pro Glu Leu Ile Phe	
215 220 225	
gga gcc act gat tat acc tct agt ata gat gta tgg tct gct ggc tgt	774
Gly Ala Thr Asp Tyr Thr Ser Ser Ile Asp Val Trp Ser Ala Gly Cys	
230 235 240 245	
gtg ttg gct gag ctg tta cta gga caa cca ata ttt cca ggg gat agt	822
Val Leu Ala Glu Leu Leu Leu Gly Gln Pro Ile Phe Pro Gly Asp Ser	
250 255 260	
ggg gtg gat cag ttg gta gaa ata atc aag gtc ctg gga act cca aca	870
Gly Val Asp Gln Leu Val Glu Ile Ile Lys Val Leu Gly Thr Pro Thr	
265 270 275	
agg gag caa atc aga gaa atg aac cca aac tac aca gaa ttt aaa ttc	918
Arg Glu Gln Ile Arg Glu Met Asn Pro Asn Tyr Thr Glu Phe Lys Phe	
280 285 290	
cct caa att aag gca cat cct tgg act aag gtc ttc cga ccc cga act	966
Pro Gln Ile Lys Ala His Pro Trp Thr Lys Val Phe Arg Pro Arg Thr	
295 300 305	

cca ccg gag gca att gca ctg tgt agc cgt ctg ctg gag tat aca cca	1014
Pro Pro Glu Ala Ile Ala Leu Cys Ser Arg Leu Leu Glu Tyr Thr Pro	
310 315 320 325	
act gcc cga cta aca cca ctg gaa gct tgt gca cat tca ttt ttt gat	1062
Thr Ala Arg Leu Thr Pro Leu Glu Ala Cys Ala His Ser Phe Phe Asp	
330 335 340	
gaa tta cgg gac cca aat gtc aaa cat cca aat ggg cga gac aca cct	1110
Glu Leu Arg Asp Pro Asn Val Lys His Pro Asn Gly Arg Asp Thr Pro	
345 350 355	
gca ctg ttc aac ttc acc act caa gaa ctg tca agt aat cca cct ctg	1158
Ala Leu Phe Asn Phe Thr Thr Gln Glu Leu Ser Ser Asn Pro Pro Leu	
360 365 370	
gct acc atc ctt att cct cct cat gct cgg att caa gca gct gct tca	1206
Ala Thr Ile Leu Ile Pro Pro His Ala Arg Ile Gln Ala Ala Ala Ser	
375 380 385	
acc ccc aca aat gcc aca gca gcg tca gat gct aat act gga gac cgt	1254
Thr Pro Thr Asn Ala Thr Ala Ala Ser Asp Ala Asn Thr Gly Asp Arg	
390 395 400 405	
gga cag acc aat aat gct gct tct gca tca gct tcc aac tcc acc tga	1302
Gly Gln Thr Asn Asn Ala Ala Ser Ala Ser Ala Ser Asn Ser Thr	
410 415 420	
acagtcccga cgagccagct gcacaggaaa aaccaccagt tacttgagtg tcaactcagca	1362
acactgggtca cgtttggaataaatatt	1389
<210> 4	
<211> 20	
<212> DNA	
<213> Artificial Sequence	
<223> PCR Primer	
<400> 4	
ttcagctttt ggcagcatga	20
<210> 5	
<211> 21	
<212> DNA	
<213> Artificial Sequence	
<223> PCR Primer	
<400> 5	
gagttgccac cactgttgctc a	21
<210> 6	
<211> 28	
<212> DNA	
<213> Artificial Sequence	
<223> PCR Probe	
<400> 6	
cttgctgccg tccttgctctc tgctaact	28

20	25	30	35	
aag gtg aca aca gtg gtg gca act cct ggg gca ggg gtc cag aca ggc				262
Lys Val Thr Thr Val Val Ala Thr Pro Gly Ala Gly Val Gln Thr Gly				
40	45	50		
cac aag aag tca gct ata cag aca cta aaa gtt gat tgg aaa tgg atc				310
His Lys Lys Ser Ala Ile Gln Thr Leu Lys Val Asp Trp Lys Trp Ile				
55	60	65		
att tgg tgt ggt ata t				326
Ile Trp Cys Gly Ile				
70				
<210> 11				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<223> Antisense Oligonucleotide				
<400> 11				
agctctccgc aaaggaggtg				20
<210> 12				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<223> Antisense Oligonucleotide				
<400> 12				
cttgacagctc tccgcaaagg				20
<210> 13				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<223> Antisense Oligonucleotide				
<400> 13				
accggcttgc agctctccgc				20
<210> 14				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<223> Antisense Oligonucleotide				
<400> 14				
aaagctgaag gctgctgcac				20
<210> 15				
<211> 20				
<212> DNA				
<213> Artificial Sequence				
<223> Antisense Oligonucleotide				

<400> 15 ctaactttca tgctgccaaa	20
<210> 16 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 16 tctctgctaa ctttcatgct	20
<210> 17 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 17 tgccgtcctt gtctctgcta	20
<210> 18 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 18 ccaggagttg ccaccactgt	20
<210> 19 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 19 accaaagat ccatttccaa	20
<210> 20 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 20 tgatatacca caccaaata	20
<210> 21 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	

<400> 21
 tggcttgata taccacacca 20

<210> 22
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 22
 aagtttggct tgatatacca 20

<210> 23
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 23
 tcacaaagtt tggcttgata 20

<210> 24
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 24
 tcttgtcctg caatactttc 20

<210> 25
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 25
 tctcatgatc tggagctctc 20

<210> 26
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 26
 agctttctca tgatctggag 20

<210> 27
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 27
 acagtgatct agctttctca 20

<210> 28
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 28
 ggactatggt acagtgatct 20

<210> 29
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 29
 agaaataacg caatcggact 20

<210> 30
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 30
 cctcatcttt cttctcacca 20

<210> 31
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 31
 tagacctcat ctttcttctc 20

<210> 32
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 32
 aagatagacc tcattcttct 20

<210> 33
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 33 cggaacatag tccagcacca	20
<210> 34 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 34 actgtttccg gaacatagtc	20
<210> 35 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 35 actctgtata ctgtttccgg	20
<210> 36 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 36 agtgtctggc aactctgtat	20
<210> 37 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 37 cgactatagt gtctggcaac	20
<210> 38 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 38 gctcgactat agtgtctggc	20
<210> 39 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	

<400> 39
 cgtctgtttg gctcgactat 20

<210> 40
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 40
 atacatatac aacttgacat 20

<210> 41
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 41
 atataggcta aacttcggaa 20

<210> 42
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 42
 aaaggaatgg atataggcta 20

<210> 43
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 43
 tatcccgatg gcagattcca 20

<210> 44
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 44
 ggatccaaca agaggttctg 20

<210> 45
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 45 tcacagagtt ttaatacagc	20
<210> 46 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 46 gctgctttgc acttccaaag	20
<210> 47 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 47 gaacagatat acgaaacatt	20
<210> 48 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 48 tggtgcccta tagtaccgag	20
<210> 49 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 49 gatcaactct ggtgccctat	20
<210> 50 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 50 aagatcaact ctggtgccct	20
<210> 51 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	

<400> 51
 gaccatacat ctatactaga 20

<210> 52
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 52
 gcagaccata catctatact 20

<210> 53
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 53
 gttgtcctag taacagctca 20

<210> 54
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 54
 ggaaatattg gttgtcctag 20

<210> 55
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 55
 accaactgat ccacaccact 20

<210> 56
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 56
 ttcatttctc tgatttgctc 20

<210> 57
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 57
 tttgggttca tttctctgat 20

<210> 58
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 58
 caattgcctc cggtggagtt 20

<210> 59
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 59
 gggcagttgg tgtatactcc 20

<210> 60
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 60
 caagcttcca gtggtgtag 20

<210> 61
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 61
 gtgcacaagc ttccagtggt 20

<210> 62
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 62
 tgaatgtgca caagcttcca 20

<210> 63
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 63
 aaaaatgaat gtgcacaagc 20

<210> 64
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 64
 taattcatca aaaaatgaat 20

<210> 65
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 65
 ttgggtcccg taattcatca 20

<210> 66
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 66
 catttgatg tttgacattt 20

<210> 67
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 67
 ggtgtgtctc gccatttgg 20

<210> 68
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 68
 tgcaggtgtg tctcgcccat 20

<210> 69
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 69
 ttgaagagtg caggtgtgtc 20

<210> 70
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 70
 cttgacagtt cttgagtggc 20

<210> 71
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 71
 gaataaggat ggtagccaga 20

<210> 72
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 72
 ccgagcatga ggaggaataa 20

<210> 73
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 73
 agcagctgct tgaatccgag 20

<210> 74
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 74
 ggtctgtcca cggtctccag 20

<210> 75
 <211> 20
 <212> DNA
 <213> Artificial Sequence
 <223> Antisense Oligonucleotide

<400> 75 ttattggtct gtccacggtc	20
<210> 76 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 76 ttggaagctg atgcagaagc	20
<210> 77 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 77 cgggactgtt caggtggagt	20
<210> 78 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 78 agtaactggt ggtttttcct	20
<210> 79 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 79 gctgagtgac actcaagtaa	20
<210> 80 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	
<400> 80 gtgaccagtg ttgctgagtg	20
<210> 81 <211> 20 <212> DNA <213> Artificial Sequence	
<223> Antisense Oligonucleotide	

<400> 81
acgtgaccag tgttgctgag 20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 82
caaacgtgac cagtgttgct 20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 83
ctttccaaac gtgaccagtg 20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 84
gttaggttaa cgataaatgc 20

<210> 85
<211> 20
<212> DNA
<213> Artificial Sequence

<223> Antisense Oligonucleotide

<400> 85
cttttcttcc ttttgtcttt 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01085

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/7088, 31/7115, 31/712, 31/7125; C07H 21/00; C12N 5/06;
US CL : 435/375; 514/44; 536/24.5

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 375; 514/44; 536/24.3, 24.31, 24.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,837,853 A (TAKASHIMA et al) 17 November 1998, see column 3, lines 15-49;	1-5, 11-15, 18, 19
—	column 4, line 27, to column 7, line 26; column 11, line 36, to column 12, line 29; SEQ.	-----
Y	ID. NOS: 7 and 12.	1-19
X,P	US 5,057,117 A (HARRISON et al.) 02 May 2000, see abstract; column 2, lines 15-29;	1, 2, 11-19
—	column 3, lines 31-32; column 11, lines 10-28; column 12, lines 26-62.	-----
Y,P		1-19
X	EP 0 616 032 A2 (MITSUBISHI KASEI CORPORATION) 21 September 1994, see page	1-5, 11-15, 18, 19
—	3, lines, 18-30; page 3, line 57, to page 5, line 6; page 5, line 30, to page 6, line 2, page	-----
Y	9, lines 8-51, claims 3, 4, 7, and 8.	1-19

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

23 March 2001 (23.03.2001)

Date of mailing of the international search report

03 MAY 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Thomas G. Larson, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/01085

Continuation of B. FIELDS SEARCHED Item 3: USPAT, DWPI, JPABS, EPABS, EMBL, GENBANK, BIOSIS, CAPLUS, MEDLINE

Search terms: glycogen synthase kinase 3 beta, GSK3B, tau protein kinase I, TPK-I, antisense, anti sense, ribozyme